<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74010</article-id><article-id pub-id-type="doi">10.7554/eLife.74010</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Individualized discovery of rare cancer drivers in global network context</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-255742"><name><surname>Petrov</surname><given-names>Iurii</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-108819"><name><surname>Alexeyenko</surname><given-names>Andrey</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8812-6481</contrib-id><email>andrej.alekseenko@scilifelab.se</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056d84691</institution-id><institution>Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet</institution></institution-wrap><addr-line><named-content content-type="city">Stockholm</named-content></addr-line><country>Sweden</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04ev03g22</institution-id><institution>Science for Life Laboratory</institution></institution-wrap><addr-line><named-content content-type="city">Solna</named-content></addr-line><country>Sweden</country></aff><aff id="aff3"><label>3</label><institution>Evi-networks, enskild konsultföretag</institution><addr-line><named-content content-type="city">Huddinge</named-content></addr-line><country>Sweden</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Robles-Espinoza</surname><given-names>C Daniela</given-names></name><role>Reviewing Editor</role><aff><institution>International Laboratory for Human Genome Research</institution><country>Mexico</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Walczak</surname><given-names>Aleksandra M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>CNRS LPENS</institution></institution-wrap><country>France</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>20</day><month>05</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e74010</elocation-id><history><date date-type="received" iso-8601-date="2021-09-17"><day>17</day><month>09</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-05-20"><day>20</day><month>05</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-10-05"><day>05</day><month>10</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.10.04.463007"/></event></pub-history><permissions><copyright-statement>© 2022, Petrov and Alexeyenko</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Petrov and Alexeyenko</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74010-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74010-figures-v2.pdf"/><abstract><p>Late advances in genome sequencing expanded the space of known cancer driver genes several-fold. However, most of this surge was based on computational analysis of somatic mutation frequencies and/or their impact on the protein function. On the contrary, experimental research necessarily accounted for functional context of mutations interacting with other genes and conferring cancer phenotypes. Eventually, just such results become ‘hard currency’ of cancer biology. The new method, NEAdriver employs knowledge accumulated thus far in the form of global interaction network and functionally annotated pathways in order to recover known and predict novel driver genes. The driver discovery was individualized by accounting for mutations’ co-occurrence in each tumour genome – as an alternative to summarizing information over the whole cancer patient cohorts. For each somatic genome change, probabilistic estimates from two lanes of network analysis were combined into joint likelihoods of being a driver. Thus, ability to detect previously unnoticed candidate driver events emerged from combining individual genomic context with network perspective. The procedure was applied to 10 largest cancer cohorts followed by evaluating error rates against previous cancer gene sets. The discovered driver combinations were shown to be informative on cancer outcome. This revealed driver genes with individually sparse mutation patterns that would not be detectable by other computational methods and related to cancer biology domains poorly covered by previous analyses. In particular, recurrent mutations of collagen, laminin, and integrin genes were observed in the adenocarcinoma and glioblastoma cancers. Considering constellation patterns of candidate drivers in individual cancer genomes opens a novel avenue for personalized cancer medicine.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>network analysis</kwd><kwd>driver mutations</kwd><kwd>significance</kwd><kwd>error rate</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsrådet</institution></institution-wrap></funding-source><award-id>2016-04940</award-id><principal-award-recipient><name><surname>Petrov</surname><given-names>Iurii</given-names></name><name><surname>Alexeyenko</surname><given-names>Andrey</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Method NEAdriver employs knowledge from global networks to predict novel cancer driver genes in an individualized manner, which is done by accounting for mutations’ co-occurrence in each tumor genome and rigorous statistical evaluation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Carcinogenesis is a complex, multi-step process, during which cellular genomes accumulate new, somatic alterations which might also interact with e.g. germline variants. Mutations that cause or facilitate cancer initiation and progression are called drivers. On the other hand, many mutations occur spuriously due to impairment of chromosome maintenance, replication errors etc. Therefore, a cancer cell genome usually represents a mixture of driver and passenger mutations (<xref ref-type="bibr" rid="bib84">Torkamani et al., 2009</xref>). Apart from the boosting genome instability that generates passengers as well as additional drivers, cancer cells should acquire selective advantages, such as apoptosis evasion, unconstrained proliferation, or survival in low-oxygen environment which correspond to the hallmarks of cancer (<xref ref-type="bibr" rid="bib29">Hanahan and Weinberg, 2011</xref>). Given the avalanche of new data from cancer genome sequencing, it became possible to complement earlier known, ‘core’ cancer gene sets with multitudes of computationally inferred drivers.</p><p>The existing computational approaches to cancer driver discovery can be classified into three major method groups, possibly combined within a certain implementation:</p><list list-type="order"><list-item><p>Mutation frequency analyses, based on the idea that driver genes appear mutated more often than expected by chance (<xref ref-type="bibr" rid="bib40">Lawrence et al., 2014</xref>)<sup>,</sup>(<xref ref-type="bibr" rid="bib51">Mermel et al., 2011</xref>). In order to keep discovering novel drivers, frequency methods should capture increasingly more rare events (<xref ref-type="bibr" rid="bib88">Vogelstein et al., 2013</xref>) – which is limited by practically achievable genomics dataset sizes. As an example, MuSiC driver analysis included only point mutations (PM) that occurred in more than 5% of tumours (<xref ref-type="bibr" rid="bib18">Dees et al., 2012</xref>). A close-to-comprehensive frequency analysis might require 600–5000 samples per tumour type, depending on background mutation frequency (<xref ref-type="bibr" rid="bib41">Lawrence et al., 2015</xref>). Thus, despite all the advancements, cancer sequencing often fails to identify any driver events in a certain cancer genome.</p></list-item><list-item><p>Evaluation of functional impact of sequence alterations using protein structural information, physicochemical features, evolutionary conservation etc. (<xref ref-type="bibr" rid="bib66">Reva et al., 2011</xref>)<sup>,</sup>(<xref ref-type="bibr" rid="bib76">Sim et al., 2012</xref>)<sup>,</sup>(<xref ref-type="bibr" rid="bib1">Adzhubei et al., 2010</xref>) Such methods might also include frequency analyses and were often trained on smaller sets of best known cancer genes (<xref ref-type="bibr" rid="bib47">Martelotto et al., 2014</xref>) which might lead to overfitting. Although some positive correlation with higher mutation frequency has been demonstrated (<xref ref-type="bibr" rid="bib27">Gnad et al., 2013</xref>), predictions by different methods often disagreed even for most studied genes (<xref ref-type="bibr" rid="bib81">Tamborero et al., 2013</xref>).</p></list-item><list-item><p>Commonality of protein function to disease genes established via expert judgement or computational analysis of literature associations (<xref ref-type="bibr" rid="bib34">Jimenez-Sanchez et al., 2001</xref>) and global gene network context (<xref ref-type="bibr" rid="bib83">Torkamani and Schork, 2009</xref><sup>;</sup> <xref ref-type="bibr" rid="bib85">Tranchevent et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">Doncheva et al., 2012</xref>). In contrast to the approaches described above, this ‘guilt-by-association’ (GBA) methodology (<xref ref-type="bibr" rid="bib56">Oliver, 2000</xref>) did not require information on mutations per se and could thus be applied to all known genes. Most commonly, likelihood of a general function such as cancer ‘driverness’ was assigned by a GBA algorithm alone which, when applied to all the genes, generated thousands of predictions with prohibitively high false positive rates (FPR).</p></list-item></list><p>A particular challenge would be to identify drivers among gene copy number alterations (CNA), which may encompass longer chromosomal regions with multiple genes were gained or lost at once, ‘competing’ for a driver role assignment. Therefore, CNA genes were often excluded from the analyses described above.</p><p>Network analysis is an important tool for cancer driver gene discovery: it not only implements the GBA principle, but also assesses genomic events by employing the network-defined entities, such as modules and pathways. Non-biological algorithms of network analysis, such as PageRank (<xref ref-type="bibr" rid="bib58">Page et al., 1999</xref>) and Random Walk with Restart (RWR), exist since long ago and were adopted, usually with minimal or no changes, by bioinformatics frameworks (<xref ref-type="bibr" rid="bib20">Erten et al., 2011</xref>; <xref ref-type="bibr" rid="bib21">Fang and Gough, 2014</xref>; <xref ref-type="bibr" rid="bib38">Köhler et al., 2008</xref>; <xref ref-type="bibr" rid="bib57">Ozturk et al., 2018</xref>; <xref ref-type="bibr" rid="bib90">Winter et al., 2012</xref>). For a combination of natural and historical reasons, interpretation of these algorithms tend to focus on network hubs, which could miss novel disease genes with lower node degrees (<xref ref-type="bibr" rid="bib5">Barabási et al., 2011</xref>). Furthermore, GBA methods might be work regardless of predefined pathways, for example consider expression correlates (<xref ref-type="bibr" rid="bib83">Torkamani and Schork, 2009</xref>), physical interactions (<xref ref-type="bibr" rid="bib16">Ciriello et al., 2012</xref>), or shared annotations (<xref ref-type="bibr" rid="bib23">Freudenberg and Propping, 2002</xref>). Such methods though, when applied to either all or to frequently mutated genes, would either suffer from the high false positive rate or miss rare drivers. Another solution was offered by the method of network enrichment analysis (NEA)(<xref ref-type="bibr" rid="bib3">Alexeyenko et al., 2012</xref>), where network connectivity is normalized by gene node degrees, which allowed studying genes poorly covered with experimental data. The other advantage of NEA is its high sensitivity and robustness due to considering the multitude of edges available in the global network (<xref ref-type="bibr" rid="bib33">Jeggari and Alexeyenko, 2017</xref>; <xref ref-type="bibr" rid="bib22">Franco et al., 2019</xref>). The concept of enrichment, that is detection of signal that prevails over noise is implemented in NEA via counting network edges that connect gene nodes. Significant excess of actual number of edges over expected by chance can distinguish functionally relevant genes, that is drivers differ from passengers by relevant fragments of network connectivity.</p><p>The above-mentioned problem of high FPR can be efficiently addressed by combining probabilities from multiple evidence channels. In the presented analysis we did that in a three-pronged way. First, we reduced FPR by considering only genes altered in a given tumor genome, whereas genes mutated elsewhere were ignored. Second, we employed the idea that driver mutations of mutated gene sets (MGS) in individual samples should be mutually related and identified such cases by network enrichment against each other, that is within MGS. Third, we detected driver roles by summarizing network connectivity of MGS to diverse potentially informative pathways. Since the full set of such pathways was not known in advance, we started from hundreds pathway profiles, followed by feature selection and creation of predictive cohort-specific sparse models. Combining the two predictors decreased FPR even further.</p><p>We applied the analysis pipeline to nine largest TCGA cohorts as well as to a newly compiled meta-cohort of medulloblastoma (MB). We evaluate agreement between our and earlier published driver sets, relative contributions of the driver score components, significance, prediction error rates, and prove the method robustness across over a broad range of mutation rates (from very low in MB to very high in skin melanoma) and variable disease aggressiveness. We demonstrate functional relations between driver mutation patterns, gene expression in affected pathways, and patient survival. Finally, the analysis exposed so far underestimated protein categories with individually rare genomic alterations in their members which appeared essential for several cancer hallmarks.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Algorithm outline: two evidence channels for driver prediction</title><p>The procedure evaluated likelihood of each genomic alteration reported in MAF or CNA files after level 3 analysis being a driver in the given tumor genome. This was done by considering functional network context in two parallel, independent analysis channels (<xref ref-type="fig" rid="fig1">Figure 1</xref>):</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Visualization of NEAdriver analysis.</title><p>(<bold>A</bold>) Workflow according to the algorithm described in Methods. (<bold>B</bold>) Examples of MutSet analysis to mutation gene sets in two cohorts.(<bold>C</bold>) Example PathReg analysis in MB cohort. Legend to nodes and edges.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig1-v2.tif"/></fig><sec id="s2-1-1"><title>MutSet channel</title><p>Evaluated network enrichment between each altered gene <italic>m</italic> (<italic>m</italic>∈ MGS) and the constellation of all other altered genes <italic>n</italic> (<italic>n</italic>∈ MGS; <italic>n</italic> ≠ <italic>m</italic>). The resulting NEA scores <inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>↔</mml:mo><mml:mi>M</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mi> </mml:mi><mml:mi> </mml:mi></mml:math></inline-formula> accounted for network degrees of the interacting MGS genes and expressed strength of the cumulative interaction compared to a value expected by chance, that is when <italic>m</italic> would be functionally unrelated to the rest of MGS.</p></sec><sec id="s2-1-2"><title>PathReg channel</title><p>Evaluated likelihood of being a cancer driver in a two-step procedure. First, each of the <italic>N</italic> genes present in the network (N=19035) were characterized – in the same way as in MutSet – by network enrichment scores against each individual MGS. These ‘anchor’ scores <inline-formula><mml:math id="inf2"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>↔</mml:mo><mml:mi>M</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> were summarized per gene <italic>i</italic> and within each of the 10 cohorts <italic>c</italic>. The reasoning behind this was that if MGSs included some actual (but not explicitly declared) drivers, then potential cancer involvement of a gene could be expressed as a summary of its network interactions over the MGS collection. For a highly scoring gene, this should become evidence of being a driver when it was altered in a given genomic sample. The cohort-specific gene vectors called ‘anchor.summary’ should already contain all information gathered from genes’ interactions with all the MGSs. However, given that both MGSs and the available network were likely incomplete, some genes in anchor.summary vectors would not be fully evaluated. Therefore, we introduced a second step: boosting via pathway enrichment scores. Cohort-specific predictive models were created using anchor.summary vectors as independent variables (being split into training and testing halves, <italic>N’</italic>=<italic>N</italic>/2 and N’’=<italic>N</italic>/2). Dependent variables for the models were provided by pre-calculated NEA scores for the same <italic>N</italic> genes against a collection of <italic>P</italic>=320 pathways, generally called functional gene sets (FGS), forming an N×<italic>P</italic> matrix. Then sparse multivariate models (k=31…83 pathways with non-zero coefficients) were obtained via the lasso training procedure under cross-validation and by controlling performance and robustness with error terms and information criteria. Due to big sample sizes (<italic>N’</italic>~10<sup>4</sup>), the models reproduced well on the test sets (Spearman rank R between observed and predicted vectors of anchor.summary were 0.62…0.79; Suppl.File 1). The sparse models produced cohort-specific PathReg scores for each of the <italic>N</italic> genes. Using published driver sets as references, performance of the scores was compared to the original anchor.summary, which demonstrated clear superiority of PathReg and thus gain in driver-related information via pathway enrichment. Thus, MutSet estimated driverness strictly in the context of individual cancer genomes, whereas PathReg models were originally derived from individual MGSs and then presented as universal, cohort-specific values. Importantly, neither of the two employed information on mutation frequencies. Enrichment heatmaps for genes that scored highest in PathReg versus pathways included in the models are presented in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p>Similarly to NetSig5000 method (<xref ref-type="bibr" rid="bib30">Horn et al., 2018</xref>), we also tested the approach of network evaluation of mutations against sets of most frequently mutated genes, but this channel did not yield any further advantage and was not used. The MutSet and PathReg scores were calibrated and converted into <italic>p</italic> and respective <italic>q</italic> (false discovery rate) values. Evidence from MutSet and PathReg was combined under OR condition, that is the resulting product q(MutSet&amp;PathReg)=q(MutSet)*q(PathReg) reported the probability of NOT being a driver despite positive evidence obtained from either channel. In this way, MGSs were reduced to driver gene sets, DGS (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). For the purposes of further testing, the DGSs were defined at two significance thresholds q(MutSet&amp;PathReg)&lt;0.05 and q(MutSet&amp;PathReg)&lt;0.01. Under the former cutoff the fractions of drivers were 14…67% larger than under the latter (<xref ref-type="table" rid="table1">Table 1</xref>). The full lists of genes for the ten cohorts are presented in the summary tables (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Fractions of individual alterations and unique genes predicted by NEAdriver.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" valign="bottom"/><th align="center" valign="bottom">BRCA</th><th align="center" valign="bottom">COAD</th><th align="center" valign="bottom">GBM</th><th align="center" valign="bottom">LUAD</th><th align="center" valign="bottom">LUSC</th><th align="center" valign="bottom">OV</th><th align="center" valign="bottom">PAAD</th><th align="center" valign="bottom">PRAD</th><th align="center" valign="bottom">SKCM</th><th align="center" valign="bottom">MB</th></tr></thead><tbody><tr><td align="left" rowspan="3" valign="bottom">No. of</td><td align="left" valign="bottom">genes</td><td align="center" valign="bottom">17,216</td><td align="center" valign="bottom">16,553</td><td align="center" valign="bottom">11,484</td><td align="center" valign="bottom">17,028</td><td align="center" valign="bottom">14,853</td><td align="center" valign="bottom">14,055</td><td align="center" valign="bottom">14,766</td><td align="center" valign="bottom">11,660</td><td align="center" valign="bottom">17,253</td><td align="center" valign="bottom">18,244</td></tr><tr><td align="left" valign="bottom">samples</td><td align="center" valign="bottom">989</td><td align="center" valign="bottom">269</td><td align="center" valign="bottom">284</td><td align="center" valign="bottom">519</td><td align="center" valign="bottom">178</td><td align="center" valign="bottom">461</td><td align="center" valign="bottom">185</td><td align="center" valign="bottom">300</td><td align="center" valign="bottom">346</td><td align="center" valign="bottom">564</td></tr><tr><td align="left" valign="bottom">alterations<break/>(PM&amp;CNA)</td><td align="center" valign="bottom">158,982</td><td align="center" valign="bottom">115,250</td><td align="center" valign="bottom">36,230</td><td align="center" valign="bottom">193,285</td><td align="center" valign="bottom">71,238</td><td align="center" valign="bottom">81,719</td><td align="center" valign="bottom">64,027</td><td align="center" valign="bottom">33,985</td><td align="center" valign="bottom">230,159</td><td align="center" valign="bottom">96,263</td></tr><tr><td align="left" rowspan="3" valign="bottom">Fraction of cases when received q&lt;0.05</td><td align="left" valign="bottom">PathReg</td><td align="center" valign="bottom">1.55%</td><td align="center" valign="bottom">2.23%</td><td align="center" valign="bottom">3.81%</td><td align="center" valign="bottom">3.02%</td><td align="center" valign="bottom">2.94%</td><td align="center" valign="bottom">3.81%</td><td align="center" valign="bottom">0.16%</td><td align="center" valign="bottom">3.44%</td><td align="center" valign="bottom">4.42%</td><td align="center" valign="bottom">0.06%</td></tr><tr><td align="left" valign="bottom">MutSet</td><td align="center" valign="bottom">2.95%</td><td align="center" valign="bottom">3.52%</td><td align="center" valign="bottom">3.75%</td><td align="center" valign="bottom">4.88%</td><td align="center" valign="bottom">3.68%</td><td align="center" valign="bottom">3.53%</td><td align="center" valign="bottom">1.21%</td><td align="center" valign="bottom">2.62%</td><td align="center" valign="bottom">9.24%</td><td align="center" valign="bottom">4.48%</td></tr><tr><td align="left" valign="bottom">PathReg &amp; MutSet</td><td align="center" valign="bottom">8.52%</td><td align="center" valign="bottom">6.81%</td><td align="center" valign="bottom">10.63%</td><td align="center" valign="bottom">9.67%</td><td align="center" valign="bottom">7.72%</td><td align="center" valign="bottom">9.15%</td><td align="center" valign="bottom">2.79%</td><td align="center" valign="bottom">7.74%</td><td align="center" valign="bottom">13.42%</td><td align="center" valign="bottom">9.14%</td></tr><tr><td align="left" rowspan="3" valign="bottom">Fraction of cases when received q&lt;0.01</td><td align="left" valign="bottom">PathReg</td><td align="center" valign="bottom">0.55%</td><td align="center" valign="bottom">1.37%</td><td align="center" valign="bottom">1.24%</td><td align="center" valign="bottom">2.41%</td><td align="center" valign="bottom">2.3%</td><td align="center" valign="bottom">2.16%</td><td align="center" valign="bottom">0.03%</td><td align="center" valign="bottom">2.80%</td><td align="center" valign="bottom">3.17%</td><td align="center" valign="bottom">0.02%</td></tr><tr><td align="left" valign="bottom">MutSet</td><td align="center" valign="bottom">2.17%</td><td align="center" valign="bottom">2.77%</td><td align="center" valign="bottom">2.65%</td><td align="center" valign="bottom">4.01%</td><td align="center" valign="bottom">2.57%</td><td align="center" valign="bottom">2.68%</td><td align="center" valign="bottom">0.70%</td><td align="center" valign="bottom">1.80%</td><td align="center" valign="bottom">8.00%</td><td align="center" valign="bottom">3.65%</td></tr><tr><td align="left" valign="bottom">PathReg &amp; MutSet</td><td align="center" valign="bottom">7.11%</td><td align="center" valign="bottom">5.57%</td><td align="center" valign="bottom">7.81%</td><td align="center" valign="bottom">8.21%</td><td align="center" valign="bottom">6.16%</td><td align="center" valign="bottom">7.17%</td><td align="center" valign="bottom">1.65%</td><td align="center" valign="bottom">6%</td><td align="center" valign="bottom">11.81%</td><td align="center" valign="bottom">6.98%</td></tr><tr><td align="left" colspan="2" valign="bottom">No. of genes which received q(PathReg&amp;MutSet)&lt;0.05 in&gt;90% samples</td><td align="center" valign="bottom">221</td><td align="center" valign="bottom">343</td><td align="center" valign="bottom">226</td><td align="center" valign="bottom">498</td><td align="center" valign="bottom">334</td><td align="center" valign="bottom">270</td><td align="center" valign="bottom">14</td><td align="center" valign="bottom">180</td><td align="center" valign="bottom">766</td><td align="center" valign="bottom">5</td></tr></tbody></table></table-wrap></sec></sec><sec id="s2-2"><title>Comparison with alternative gene sets</title><p>We first evaluated performance of the method [q(MutSet&amp;PathReg)&lt;0.05] by ability to detect gene members of 11 alternative reference sets, which were either derived from curated resources or published as computational analysis results (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Overlaps with the reference sets were mostly significant: 90 out of 110 pairwise comparisons by Fisher’s exact test and 61 out 110 by Mann-Whitney test received a Bonferroni-adjusted p-value below 0.05.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Agreement between NEAdriver and reference gene sets.</title><p>(<bold>A</bold>) The heatmap matrix elements represent overlap between the cohort-specific sets of predicted NEAdriver gene sets at q(MutSet&amp;PathReg)&lt;0.05 and gene sets from curated resources and alternative methods. Row and column widths are proportional to gene sets sizes. All the reference gene sets had fixed, ‘pan-cancer’ member sets independent of cancer site, except Cancer Gene Census, IntOGen, and literature/KEGG site-specific sets, for which size ranges are given. B. Network enrichment of the cancer gene sets with regard to 50 hallmarks (<xref ref-type="bibr" rid="bib43">Liberzon et al., 2015</xref>). NEAdriver sets defined at q(MutSet&amp;PathReg)&lt;0.05 are represented by 165 genes for each cohort, most frequent across its samples(n=165 was chosen for being half of the size of FoundationOne set).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Network enrichment of the cancer gene sets with regard to 50 hallmarks.</title><p>Sets of genes which most frequently received confident (q&lt;0.05) scores from MutSet and PathReg channels in each cohort were analyzed in terms of network connectivity against the 50 hallmarks (<xref ref-type="bibr" rid="bib43">Liberzon et al., 2015</xref>). Point mutation gene sets (MGS), represented by 165 most frequent genes for each cohort.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>NEAdriver sets defined at q(MutSet)&lt;0.05 and represented by 165 genes for each cohort.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>NEAdriver sets defined at q(PathReg)&lt;0.05 and represented by 165 genes for each cohort.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>Correlations between from PathReg and MutSet channels.</title><p>The points represent positions of individual hallmarks in each cohort.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig2-figsupp4-v2.tif"/></fig></fig-group><p>In order to see differences between functional landscapes of NEAdriver (the sets of predicted drivers at (q(MutSet&amp;PathReg)&lt;0.05) vs. the alternative sets), we calculated network enrichment scores of each gene set as a whole versus each of 50 hallmark gene sets (<xref ref-type="bibr" rid="bib43">Liberzon et al., 2015</xref>; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). The heatmap revealed that NEAdriver detected genes from a different hallmark subspace than most of the computational methods. On the other hand, the NEAdriver predictions often clustered together with the curated sets KEGG05200 ‘Pathways in cancer’ and the union of five ‘general’ (not cohort-specific) cancer-relevant KEGG gene sets. Similar patterns were observed while looking at the outputs from PathReg and MutSet channels separately, although the former was somewhat closer to the curated sets (Figure Supplements to <xref ref-type="fig" rid="fig2">Figure 2B</xref>). Compared to the computational methods, the NEAdriver sets and the curated sets showed higher enrichment in EMT, angiogenesis, and suppressed KRAS signaling, glycolysis, inflammatory response, and hypoxia while depleted in cell cycle, DNA replication/repair, peroxisome as well as MYC and mTOR signaling. For comparison, the computational sets were much more similar to the original, full MGSs (Figure Supplement to <xref ref-type="fig" rid="fig2">Figure 2B</xref>), which confirmed that the NEAdriver pattern was functionally specific and distinct rather than reflected the initial mutation composition. We also noted that nearly all the alternative cohorts (except MutSig) abounded in genes with higher network degree, which were likely better known and studied than the genes predicted with NEAdriver. Node degrees of the latter were closer to an average level, as illustrated by comparisons against random gene samples (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Remarkably, the network-based method NetSig5000 also prioritized genes with higher node degree.</p></sec><sec id="s2-3"><title>Estimation of discovery rates</title><p>The same reference gene sets were used for a more detailed evaluation of NEAdriver error rates. The best combination of true positive and true negative rates was found against the gold standard cohort-specific sets, which were either literature-based or available as KEGG pathways (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref> and upper left plots in Figure Supplements to <xref ref-type="fig" rid="fig3">Figure 3</xref>), except BRCA cohort, where better results were found for NetSig5000 set which was derived from just this cohort (<xref ref-type="bibr" rid="bib30">Horn et al., 2018</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks.</title><p>Two cohorts with very low versus high passenger mutation load, medulloblastoma (MB: <bold>A,C,E</bold>) and skin cutaneous melanoma (SKCM: <bold>B,D,F</bold>), represent contrast conditions for computational driver discovery. The NEAdriver predictions were quantified by the cumulative statistic q(MutSet&amp;PathReg)&lt;0.05 and matched to reference sets. (<bold>A</bold>) and (<bold>B</bold>): ROC curves in the space of true positive versus false positive rates in the classical definition of ‘precision’. (<bold>C</bold>) and (<bold>D</bold>): Precision-recall curves where precision was calculated via inclusion of odds ‘driver/non-driver’.(<bold>E</bold> and <bold>F</bold>) calibration of positive predictive value, PPV against false discovery rate (q~1 – PPV; solid lines) and modeling of PPV in presence of true, but yet unknown drivers (dot-dashed lines) using site-specific and pan-cancer benchmarks. The dotted vertical cutoff lines referto cancer site specific pathway sets, taken from either to the literature or respective KEGG pathway. Cutoffs in (<bold>C</bold>) and (<bold>D</bold>) display q(MutSet&amp;PathReg) values, whereas TP counts in (<bold>E</bold>) and (<bold>F</bold>) are numbers of unique site-specific genes discovered under variable q(MutSet&amp;PathReg) threshold shown at X-axis.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks.</title><p>separate cohort files consisting of four panes each: Upper left: ROC curves in the space of true positive versus false positive rates in the classical definition of ‘precision’. Upper right: Precision-recall curves accounting for true and false positives as given by each gold standard set. Bottom left: Precision-recall curves where precision was calculated via inclusion of odds ‘driver/non-driver’. Bottom right: calibration of positive predictive value against false discovery rate (q~1 – PPV; solid lines) and modeling of PPV in presence of true yet unknown drivers (dot-dashed lines).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, all cohorts.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, PRAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, PAAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp4-v2.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 5.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, OV.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp5-v2.tif"/></fig><fig id="fig3s6" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 6.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, LUSC.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp6-v2.tif"/></fig><fig id="fig3s7" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 7.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, LUAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp7-v2.tif"/></fig><fig id="fig3s8" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 8.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, GBM.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp8-v2.tif"/></fig><fig id="fig3s9" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 9.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, COAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp9-v2.tif"/></fig><fig id="fig3s10" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 10.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, BRCA.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig3-figsupp10-v2.tif"/></fig></fig-group><p>Precision was first estimated using the common definition as fraction of true positives among all positives:<disp-formula id="equ1"><mml:math id="m1"><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mfrac bevelled="true"><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>If applied to the full set of <italic>n</italic> genes, regardless of their mutation status in specific cancer genomes – which corresponded to GBA approach – then these estimates appeared very low and never exceeded 20% at TPR = 10% (upper right plots in Figure Supplements to <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>A more advanced estimate could be provided by using the hybrid positive predictive value (PPV) formula by John Ioannidis (<xref ref-type="bibr" rid="bib32">Ioannidis, 2005</xref>), where the frequentist terms – error rates of types I and II – were combined with odds (i.e. the ratio of actual drivers versus non-drivers among the mutated genes), which represented a Bayesian component:<disp-formula id="equ2"><mml:math id="m2"><mml:mi>P</mml:mi><mml:mi>P</mml:mi><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mfrac bevelled="true"><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:mfenced><mml:mi>*</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>β</mml:mi><mml:mo>)</mml:mo><mml:mi>*</mml:mi><mml:mi>R</mml:mi><mml:mo>+</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>The odds could be estimated from the union of all test results on the cohort’s MGSs as<disp-formula id="equ3"><mml:math id="m3"><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mfrac bevelled="true"><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>By expanding the Bayesian approach, the type I and type II errors would be, respectively: <inline-formula><mml:math id="inf3"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:mfrac bevelled="true"><mml:mrow><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>F</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> and <inline-formula><mml:math id="inf4"><mml:mi>β</mml:mi><mml:mo>=</mml:mo><mml:mfrac bevelled="true"><mml:mrow><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>P</mml:mi><mml:mo>+</mml:mo><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>.</p><p>The value of FP + TN could be approximated as the total number of genes, since the number of drivers (TP and FN) should be negligible compared to that.</p><p>However, estimating the TP and FN via reference (gold standard) sets was more challenging, since the source publications and databases never claimed that their gene sets are truly complete. Thus, PPV estimates were particularly sensitive to biases in TP and FN and we therefore tried each of the nine sets. PPV ranged from 30% to 70% at TPR = 10%, but even at TPR = 100% almost never dropped below 20% (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref> and all cohorts in Figure Supplements to <xref ref-type="fig" rid="fig3">Figure 3</xref>). Again, the best performance was achieved using the literature/KEGG sets (PPV = 44…68% at TPR = 10%).</p><p>Since this approach considered any genes not listed in each given set as false findings, the PPV estimates must have been excessively conservative. Therefore, we next investigated the potential of discovering novel drivers using genes collected from site-specific literature or respective KEGG pathways. An alternative, pan-cancer estimate was made with a set of 369 ‘known cancer genes’ (<xref ref-type="bibr" rid="bib48">Martincorena et al., 2017</xref>). Applying the PPV adjustment to these sets under assumption that they were just 50% complete increased the PPV estimate by 20…30% (dotted curves at <xref ref-type="fig" rid="fig3">Figure 3E and F</xref>). Recalling that (1 – PPV) is essentially synonymous to false discovery rate (i.e. q-value) allowed us also to compare error rate estimates from the two independent approaches: the gold-standard based PPV versus the continuous NEAdriver q(MutSet&amp;PathReg). Although the relation was not linear over the range PPV = 0…100%, at PPV = 30…70% the cancer site-specific estimates were remarkably close in each of the 10 cohorts. On the other hand, the pan-cancer benchmark of 369 known (mostly computationally) cancer genes estimated NEAdriver q as inflated by 20…40% while assuming that the gene set was complete (solid lines) but well matching the PPV while assuming 50% incompleteness (dotted lines) (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref> and Figure Supplements to <xref ref-type="fig" rid="fig3">Figure 3</xref>). Therefore, we used NEAdriver q(MutSet&amp;PathReg) for reporting confidence of driver predictions in this work.</p><p>We also compared the results to a number of previously suggested network-based methods that considered impact of somatic alterations on the transcriptome: DriverNet (<xref ref-type="bibr" rid="bib6">Bashashati et al., 2012</xref>) and HotNet2 (<xref ref-type="bibr" rid="bib42">Leiserson et al., 2015</xref>) which implemented the cohort level approach as well as SCS (<xref ref-type="bibr" rid="bib28">Guo et al., 2018</xref>), OncoIMPACT (<xref ref-type="bibr" rid="bib9">Bertrand et al., 2015</xref>), and DawnRank (<xref ref-type="bibr" rid="bib31">Hou and Ma, 2014</xref>) which worked at the individualized, single-patient level. The comparison also included naïve frequency-based estimates as provided by Guo and co-authors (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). These publications presented short candidate driver lists combined over all samples. Agreement of the integrated ranks with NEAdriver confidence q(MutSet&amp;PathReg) in the four TCGA cohorts proved to be significant albeit rather weak (Spearman <italic>R</italic>=0.22…0.30). Further, we focused on lists of top 50 genes from each of the methods. In three cohorts (OV was the exception), a good agreement was found between the methods and NEAdriver (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Out of top 50 driver lists, between 9 and 41 genes received NEAdriver q(MutSet&amp;PathReg)&lt;0.05 (the overlaps were significant after Bonferroni-adjusted Fisher’s exact test p&lt;0.001).</p></sec><sec id="s2-4"><title>Rates of driver discovery versus mutation frequency and possible confounders</title><p>Driver discovery from large-scale genome sequencing might produce false positives due to various biasing factors, such as gene length, transcriptional activity, or DNA replication rate (<xref ref-type="bibr" rid="bib39">Lawrence et al., 2013</xref>). Although NEAdriver was designed to be independent from alteration frequency – in order to be thus more sensitive to rare events – we still performed in-depth analysis of NEAdriver output in relation to such factors and in comparison with alternative methods.</p><p>The genes listed by FoundationOne, MutSig, HCD, MuSiC and in particular by Cancer Gene Census and IntOGen had generally more mutation events per cohort than drivers predicted at q(MutSet&amp;PathReg)&lt;0.05 (<xref ref-type="fig" rid="fig4">Figure 4</xref>, left panes). The same tendency was observed when comparing copy number altered genes predicted by NEAdriver (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s10">10</xref> to <xref ref-type="fig" rid="fig4">Figure 4</xref>). Exceptions could only be found in SKCM cohort (which was not analysed in most of these projects) and in a few cohorts for MutSig (which implemented advanced normalization approaches). Sensitivity of NetSig5000 to rare mutations was comparable to our method – likely due to its network-based approach – but again mostly to genes with higher network degree (see details in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref>–<xref ref-type="fig" rid="fig4s20">20</xref> to <xref ref-type="fig" rid="fig4">Figure 4</xref>). On the contrary, when mutation frequencies were normalized by coding sequence length, the differences between the methods became less pronounced (<xref ref-type="fig" rid="fig4">Figure 4</xref>, right panes). This was not surprising, since shorter genes manifest mutations less frequently.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets.</title><p>Density plots shape the distributions in each of the alternative sets, predictions by NEAdriver (q(MutSet&amp;PathReg)&lt;0.05; brown dashed line), and genes not included in any of the above (‘other’; gray dotted line). Vertical lines correspond to mean values provided in the legend.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets.</title><p>tTen cohort files with density plots shaping mutation frequency distributions for genes in each of the alternative sets, predictions by NEAdriver (brown dashed line), and genes not included in any of the above (‘other’; gray dotted line). Vertical lines correspond to mean values, which are also provided in the legend.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Performance of the new driver prediction evaluated on different benchmarks, SKCM.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, PRAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, PAAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, OV.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp5-v2.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 6.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, LUSC.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp6-v2.tif"/></fig><fig id="fig4s7" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 7.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, LUSC.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp7-v2.tif"/></fig><fig id="fig4s8" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 8.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, GBM.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp8-v2.tif"/></fig><fig id="fig4s9" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 9.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, COAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp9-v2.tif"/></fig><fig id="fig4s10" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 10.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, BRCA.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp10-v2.tif"/></fig><fig id="fig4s11" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 11.</label><caption><title>Ten cohort files with density plots shaping mutation frequency distributions for genes in each of the alternative sets, predictions by NEAdriver (brown dashed line), and genes not included in any of the above (‘other’; gray dotted line).</title><p>Vertical lines correspond to mean values, which are also provided in the legend.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp11-v2.tif"/></fig><fig id="fig4s12" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 12.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, SKCM.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp12-v2.tif"/></fig><fig id="fig4s13" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 13.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, point mutations, PRAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp13-v2.tif"/></fig><fig id="fig4s14" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 14.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, point mutations, PAAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp14-v2.tif"/></fig><fig id="fig4s15" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 15.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, point mutations, OV.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp15-v2.tif"/></fig><fig id="fig4s16" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 16.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, point mutations, LUSC.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp16-v2.tif"/></fig><fig id="fig4s17" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 17.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, point mutations, LUAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp17-v2.tif"/></fig><fig id="fig4s18" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 18.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, point mutations, GBM.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp18-v2.tif"/></fig><fig id="fig4s19" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 19.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, point mutations, COAD.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp19-v2.tif"/></fig><fig id="fig4s20" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 20.</label><caption><title>Comparative analysis of point mutation frequency among genes included in cancer gene sets, point mutations, BRCA.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp20-v2.tif"/></fig><fig id="fig4s21" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 21.</label><caption><title>Boxplots comparing lengths of genes included in different sets versus rest of known genes.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig4-figsupp21-v2.tif"/></fig></fig-group><p>Lawrence and co-authors (<xref ref-type="bibr" rid="bib39">Lawrence et al., 2013</xref>) demonstrated that simply considering mutation frequency per gene without accounting for genomic factors results in multiple false positive associations. Similarly to their Figure 3 , we evaluated influence of suggested confounders, namely gene length, replication rate, expression level, and total mutation burden per sample on the NEAdriver predictions. Each of the linear models included one of these confounders together with number of mutations per cohort per gene as well as being a known driver or a known artifact. While the mentioned <xref ref-type="fig" rid="fig3">Figure 3</xref> by Lawrence and co-authors showed strong correlations of mutation rate versus replication or expression, respective correlations of NEAdriver score were not strong at all (albeit formally significant; absolute values of Kendall tau &lt;0.05; <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). NEAdriver predictions were stronger associated with gene length (absolute values of Kendall tau = 0.07…0.15) – while we also noticed such association in all the alternative gene sets (<xref ref-type="fig" rid="fig4s21">Figure 4—figure supplement 21</xref> to <xref ref-type="fig" rid="fig4">Figure 4</xref>). Also, genes of the latter sets contained point mutations more frequently and had higher mutation frequency per b.p. length, both absolute and normalized by genome-specific mutation load. This also characterized the driver set by <xref ref-type="bibr" rid="bib40">Lawrence et al., 2014</xref>, which would supposedly be least affected by these factors due to inclusion of these covariates in their models. Otherwise, probability of being predicted by NEAdriver after adjustment for gene length and TMB proved to be weak (Kendall tau &lt;0.05 in seven out of ten cohorts; <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). We also note that the replication and expression analyses must vary between tissues and datasets, while being expensive to measure (e.g. the analyses by Lawrence and colleagues used data from less than 100 cell lines).</p><p>Finally, we specifically considered ‘artefactual’ or ‘false positives’ genes that had cropped up in earlier cancer genome studies and were explicitly listed in later literature (34)(40)(41). We also included olfactory receptor genes as a whole category, supposedly prone to artifacts (although a majority these lacked any network edges and could not produce non-zero NEA scores). Among NEAdriver predictions, the fractions of any artefactual genes were much smaller than the overall false discovery rate evaluated via either q-value or PPV as described above. Only between 0.5% and 3% of the predictions were found in the artifact gene lists (upper right legends in new <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). In the cohort-specific linear models (bottom left legends), the Bonferroni-adjusted p-values for the term ‘known artifact’ were lower than 0.05 only in five cases out of the 30. The artefactual genes are text labelled in the scatterplots when surpassed significance threshold of q=0.05 (1…13 genes per cohort) and marked in the last columns of the summary tables (<xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>). For comparison, these genes made up 1…9% of any other computational set in our analysis.</p></sec><sec id="s2-5"><title>Novel findings</title><p>How many known drivers there are in individual cancer genomes and by how much the new method could expand this space? An earlier computational analysis estimated the number of point driver mutations as two to six per genome (<xref ref-type="bibr" rid="bib36">Kandoth et al., 2013</xref>). In our study – by counting any genes included in the nine alternative sets (N=1434) – the modes (most frequent count values) ranged across the cohorts between <italic>M</italic>=1…3 in MB (known to have very low somatic mutation load) to M=55 in SKCM (having typically thousands mutated genes per sample). For NEAdriver [q(MutSet&amp;PathReg)&lt;0.05], respective values per genome were lower, ranging between <italic>M</italic>=0…1 (MB) to <italic>M</italic>=50 (SKCM) (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Overlaps between these two approaches were rather modest (<italic>M</italic>=0…8). In other words, the driver candidates identified by NEAdriver were mostly novel. The overlaps between ‘alternative sets’ and NEAdriver [q(MutSet&amp;PathReg)&lt;0.01] are also presented for individual cancer genomes (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The Jaccard coefficient values, with exceptions of MB and GBM, rarely exceeded 0.3, which confirmed that NEAdriver identified mostly novel genes.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Distribution of somatic mutations versus drivers across genomic samples.</title><p>(<bold>A</bold>) Relative density plots of mutations and declared drivers. Pie charts summarize counts per genomic sample in each of the ten cohorts (height: average number of reported mutations per sample; width: number of samples in the cohort). (<bold>B</bold>) Overlap between the predictions by MutSet&amp;PathReg and the merge of alternative gene sets (1434 genes in total) color by Jaccard index (sets’ intersection divided with sets’ union). The MGS sizes (regardless of driver status) are expressed as marker size. Gaussian noise was added to marker coordinates for better readability.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig5-v2.tif"/></fig><p>Recalling that respective PPV estimates reached 50% and exceeded 75% when allowing for novel drivers, the predictions appeared fairly confident.</p></sec><sec id="s2-6"><title>Clustering patient driver sets in pathway space revealed association with survival</title><p>One of the goals of tumour molecular profiling is to discover cancer subtypes which would be informative of disease outcome or clinically meaningful otherwise. The driver genes identified with our method were mostly rare and therefore not suitable as stand-alone subtype markers. However, using NEA we could generate ‘DGS vs. FGS’ scores which summarized signals from various disparate events and thus available for every patient. We explored if DGS profiles in the FGS space could partition the cohorts by differential survival.</p><p>Indeed, the DGSs [q(MutSet&amp;PathReg)&lt;0.05] were often informative on patient survival. We tested three different clustering techniques and found that in many cases DGS scores differentiated cohorts by survival: 7…14.8% of all tests yielded significant Cox proportional hazard models (Benjamini-Hochberg FDR &lt;0.25). Furthermore, in up to 21.1% of all tested cases the significant partitions were recapitulated on test sets (while FDR estimates from Cox models were below 0.25) (see examples in <xref ref-type="fig" rid="fig6">Figure 6</xref> and full details in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). For comparison, splitting in the same framework by high vs. low tumor stage did not differentiate patients by survival (not shown).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Differential survival of patients stratified in pathway space created by network enrichment analysis of driver gene sets.</title><p>Vertical captions (brown) convey Cox proportional hazard p-values for three follow-up intervals.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Analysis of significance across survival curves.</title><p>Distribution of Spearman rank correlation coefficients for 1659 FGS in the ten cohorts and for different clustering methods.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Distribution of p-values for survival correlations from different clustering methods and agreement of P-values on train versus test data sets.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig6-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-7"><title>NEA scores based on either drivers or gene expression point to same pathways associated with survival</title><p>Finally, we checked if association of specific FGS scores with survival could be traced at the level of mRNA transcription. To this end, we derived lists of 100 patient-specific genes with expression most deviating from the cohort mean (gene expression based AGS) and looked if their NEA scores for the same FGS would also be associated with survival. By testing the 10 cohorts, 2 survival types, 3 clustering methods, and the 1659 FGSs, we identified 31 cases where the association with survival was observed for both DGS-FGS and gene expression based AGS-FGS scores (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> to <xref ref-type="fig" rid="fig6">Figure 6</xref>). The discovery of this many associations was significant in a random permutation test requiring Bonferroni-adjusted p-value &lt;0.01 while permutation test-based p-value &lt;0.0001 (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref> to <xref ref-type="fig" rid="fig6">Figure 6</xref>). Remarkably, in most of the cases opposite relations with survival between DGS and gene expression based AGSs were observed: better outcome was associated with high scores of the former while lower scores of the latter, or vice versa.</p><p>For example, MB and LUAD cohorts were differentiated by survival using NEA score profiles for two pathways (<xref ref-type="fig" rid="fig7">Figure 7</xref>). The cohort patients were represented first by DGSs (left) and then by gene expression based AGSs (right). The NEA scores reflected connectivity between pathway genes and patient genes (either DGS or gene expression based AGS). A higher NEA score would indicate that relatively many patient-specific genes were linked to the given pathway. MB cells are known to sometimes produce granulocyte colony-stimulating factor (<xref ref-type="bibr" rid="bib63">Pietsch et al., 2008</xref>), which can affect influx of granulocytes (<xref ref-type="bibr" rid="bib87">Vermeulen et al., 2017</xref>) and disease prognosis (<xref ref-type="bibr" rid="bib59">Paul et al., 2020</xref>). With regard to ‘Biocarta granulocytes pathway’, the MB patients where stratified so that higher DGS scores indicated poorer survival, whereas higher gene expression based AGS scores were associated with better survival. Subnetwork patterns for two patients exemplify this analysis (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). ALK fusion events are a well-established target for non-small cell lung cancer therapy (<xref ref-type="bibr" rid="bib72">Ross et al., 2017</xref>). While none of the patients were treated with an ALK inhibitor in LUAD cohort, ‘Biocarta ALK1 pathway’ scores for both DGS and gene-expression-based AGS were informative on overall survival within 6-year follow-up interval. Again, relations to survival were opposite for DGS versus gene-expression-based AGS scores.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Network enrichment and survival analyses of patient specific lists of drivers and differentially expressed genes.</title><p>(<bold>A</bold>) Example from MB cohort. (<bold>B</bold>) Example from LUAD cohort. Yellow borders: patient-specific gene sets including (<xref ref-type="bibr" rid="bib84">Torkamani et al., 2009</xref>) driver alterations (<italic>q(MutSet&amp;PathReg</italic>)&lt;0.05): either point mutations (stars) or copy number changes (diamonds) (<xref ref-type="bibr" rid="bib29">Hanahan and Weinberg, 2011</xref>) genes with mRNA expression most deviating compared to the rest of the cohort (rectangles) (<xref ref-type="bibr" rid="bib40">Lawrence et al., 2014</xref>) both categories 1 and 2 (rhomboids). Magenta borders: pathway genes (circles). Each gene is colored by expression in the given patient sample compared to the cohort mean. Note that pathway genes usually did not manifest genomic or strong expression changes. <bold>In figure</bold> (<bold>B</bold>) the edges combine individual network links between genes. Links within pathway not shown. Clinical and NEA data for the patients.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Clinical survival data and NEA scores for the MB and LUAD patients.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-fig7-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig7-v2.tif"/></fig></sec><sec id="s2-8"><title>Novel categories of cancer driver genes</title><p>We noticed that a large part of the connectivity with regard to functional hallmarks (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), which distinguished the NEAdriver predictions from other computational gene sets, was due to multiple collagens, laminins, and integrins predicted in most of the cohorts. These genes are typically rather long, within the 2nd quartile of protein coding gene list ranked by CDS length. Their median mutation frequencies per base pair of CDS length were just 1.5…2.5 times higher than that of all protein coding genes, which likely explains their escape from computational analyses so far. Nonetheless, across the ten studied cohorts genomic alterations occurred on average in 2–7 genes of these families per sample (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Using logistic regression with total mutation burden per sample as a covariate, we found that point mutations patterns of these genes also significantly (at FDR &lt;0.05 after adjustment for multiple testing) co-occurred pairwise: there were e.g. 84, 10, 23, and 308 such pairs in BRCA, COAD, LUAD, and PAAD cohorts, respectively.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Novel gene families in cancer driver context.</title><p>(<bold>A</bold>) Upper left fragment of a waterfall plot containing top 75 genes for collagens, laminins, integrins, and a few signaling proteins most frequently mutated in COAD cohort (269 samples in total). Genes with point mutations (PM) and copy number alterations (CNA) are colored according to gaining significance as q(MutSet&amp;PathReg)&lt;0.05 or not. (<bold>B</bold>) Point mutations connected with each other in the global network and identified as potential drivers in one genomic sample TCGA-CM-6171–01 (COAD) at q(MutSet&amp;PathReg)&lt;0.05. In particular, point mutations in COL6A3, ITGB2, and LAMA5 were also detected as significantly co-occurring across COAD cohort in a general linear model accounting for total mutation burden as covariate (FDR &lt;0.01).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74010-fig8-v2.tif"/></fig><p><xref ref-type="fig" rid="fig8">Figure 8B</xref> displays a typical subnetwork of genes that encode collagens, laminins, and integrins interconnected with heparan sulphate, fibronectin as well as a few signaling proteins – all affected with point mutations or copy number changes in the same cancer genome. This pattern explains high enrichment in network links to epithelial mesenchymal transition, apical junction, and angiogenesis hallmarks presented in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. Previously, roles of these families in for example cell migration, epithelial mesenchymal transition, or angiogenesis were rather well characterized at the structural (<xref ref-type="bibr" rid="bib2">Ahmed et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Rousselle and Scoazec, 2020</xref>; <xref ref-type="bibr" rid="bib53">Moilanen et al., 2017</xref>) and tissue-specific transcriptional (<xref ref-type="bibr" rid="bib10">Bretaud et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Mammoto et al., 2013</xref>) levels, and even suggested as markers for cancer diagnostics (<xref ref-type="bibr" rid="bib69">Risteli et al., 2014</xref>) and targets for treatment (<xref ref-type="bibr" rid="bib86">Tsuruta et al., 2008</xref>). However, they were not recognized by computational analyses, with a few exceptions: COL1A1 (34), COL5A1, COL5A3, ITGB7 (13), COL18A1 and ITGA6 (42), and none were so far included in the Cancer Gene Census or FoundationOne targeted sequencing panel.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>So far, most of projects presenting novel cancer drivers s generalized the discovery: either globally, within the pan-cancer paradigm (<xref ref-type="bibr" rid="bib11">Campbell et al., 2020</xref>; <xref ref-type="bibr" rid="bib82">The Cancer Genome Atlas Research Network et al., 2013</xref>) or within site/organ specific tumour types (<xref ref-type="bibr" rid="bib8">Berger et al., 2018</xref>), sometimes delineating subtype-specific drivers (<xref ref-type="bibr" rid="bib64">Pugh et al., 2012</xref>; <xref ref-type="bibr" rid="bib79">Sweet-Cordero and Biegel, 2019</xref>). Such approaches possess lower statistical power regarding short genes. We found that shorter genes were underrepresented in all alternative sets considered in this study, except the curated cancer pathways (Figure Supplement to <xref ref-type="fig" rid="fig4">Figure 4</xref>). Meanwhile, even rarely mutated genes can be drivers for example in absence of alterations in a ‘major’ gene, such as TP53 – but identifying such associations would require genome-wide studies at an unaffordable scale (<xref ref-type="bibr" rid="bib78">Stracquadanio et al., 2016</xref>). This situation apparently contradicts the individualized approach to cancer treatment, which suggests molecular pathological analyses for disease prognostication, administration of targeted drugs (<xref ref-type="bibr" rid="bib65">Remke et al., 2013</xref>), and discovery of novel drug targets. Currently, the majority of patients are not amenable to any approved targeted treatment since respective matching mutations occur with low prevalence. Further development of precision cancer medicine requires considering functional context of cancer genome in each patient (<xref ref-type="bibr" rid="bib89">Wheeler and Wang, 2013</xref>).</p><p>Novel approaches to driver identification is therefore urgent: while every cancer genome is expected to possess driver mutations, many cases lack any alterations in known cancer genes – which is counterintuitive and undermines the ground for targeted therapy. Due to the high mutational heterogeneity of cancer samples, frequency-based methods have reached their limits of statistical power to detect novel cancer drivers.</p><p>One should distinguish between mutation frequency as a tool to discover driver genes and the biological mechanism via which driverness is implemented. A mechanism for a given gene would be implemented at the level of individual tumors and therefore does not have to be directly associated with cohort-level statistics. Unlike of most of the methods (including many network-based ones), NEAdriver itself did not lean on the mutation frequency features. Instead, individual mutation events became input to NEAdriver and were evaluated independently of each other.</p><p>We pursued this approach via network analysis of mutated genes, by which patient-specific driver constellations should be discerned from the background of passenger burden. The network analysis – an already popular method to identify cancer genes using functional context – in our implementation was relatively less biased toward network hubs and thus more sensitive to novel driver genes. The previous guilt-by-association analyses (<xref ref-type="bibr" rid="bib38">Köhler et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Cava et al., 2018</xref>; <xref ref-type="bibr" rid="bib15">Cho et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">Reyna et al., 2020</xref>) predicted gene function based on functional connections to known functional categories. Confidence of such predictions alone, for example in absence of experimental data was very low due to rare occurrence of actual mutations and thus lower true discovery rate, as shown by John Ioannidis (<xref ref-type="bibr" rid="bib32">Ioannidis, 2005</xref>). NEAdriver was more focused due to considering concrete molecular phenotypes (<italic>de facto</italic> alterations in individual genomes) and combining relevant evidence from two network analysis channels. MutSet channel possesses an extra advantage: it can be directly, without pre-training on whole-cohort data, applied to a sequencing dataset of a single novel patient.</p><p>Since capabilities of both MutSet and PathReg could only be implemented on driver constellations of sufficient size, it was important to test NEAdriver on cancer genomes with different mutation loads. This feature varied from a few affected genes in MB to thousands in lung and skin cancers. Despite the variability of this and other biological parameters, both statistical performance and candidate drivers’ functional profiles proved to be rather close across the 10 cohorts. As an example, three pathways were systematically included in the models: hsa04020:Calcium_signaling_pathway (CS), hsa05412:Arrhythmogenic_right_ventricular_cardiomyopathy_(ARVC), and hsa05414:Dilated_cardiomyopathy (DCM). Although the role of CS in cancer was rarely considered central, cell migration and adhesion do involve modulation of cell motility and shape where ion channels and pumps play major roles, so that CS genes are known for both downregulation and functional implication in cancers (<xref ref-type="bibr" rid="bib80">Tajada and Villalobos, 2020</xref>; <xref ref-type="bibr" rid="bib61">Phan et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Litan and Langhans, 2015</xref>). ARVC and DCM are functionally close to CS, although have little overlap in member genes. At the first glance, the major factor behind MGS-CS interrelations might be the frequently mutating titin TTN. Its involvement in cardiopathies and cancer has been long argued because of its extremely long coding sequence, thus likely prone to spurious alterations (~50% of LUAD samples). However, there were many individually rare mutations, which together revealed emergent network patterns between MGSs and either CS, or ARVC, or DCM: cadherins, laminins, integrins, metalloproteases, nitric oxide synthases, ryanodine receptors, adenylate cyclases, subunits of protein kinase A etc. They contributed to the NEA scores with multiple network links so that for example the median edge counts between genes of MGSs and of the pathways were 22…45 in MB and 497…890 in LUAD. We therefore did not exclude genes commonly supposed to be ‘artefactual’ but instead labelled them in the final tables.</p><p>The cohort- and sample-specific NEAdriver predictions agreed well with nearly all tested alternative sets (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The best agreement was found for cancer-site-specific gold standard sets while less so for pan-cancer sets. The computational, mostly frequency-based sets performed worse than curated sets (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). In the functional space, NEAdriver predictions were positioned differently compared to computational and database sets, but close to curated cancer pathway sets (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), which confirmed both novelty and relevance of NEAdriver findings. The latter also differed from most of the alternative sets in having much less bias in regard of network node degrees and gene length.</p><p>A realistic estimate of the true discovery rate for NEAdriver predictions was obtained by accounting for putative drivers not included of the gold standard sets, so that PPV could be as high as 78%...88% at the q(mutSet&amp;PathReg)=0.05, which was verified by the two alternative ways of PPV calculation using four different gold standards (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>). The efficiency of NEAdriver was confirmed by the ability of DGS to stratify patients by survival (<xref ref-type="fig" rid="fig6">Figure 6</xref>) and the striking tendency of same pathways being associated with survival via both mutation- and expression-based patient scores (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><p>Obviously, NEAdriver alone would miss events detectable by other methods, for example when certain ‘stand-alone drivers’ impose strong effects on their own (TP53, APC etc.), without apparent interaction with other genes. This creates an incentive for creating a combined methodology and a toolbox in the future. But already now our analysis identified hundreds of somatic gene alterations that had not been deemed functional in previous research. After evaluation performed in multiple ways, the body of predictions appears confident, providing a set of provable research hypotheses and suggesting new strategies for cancer prognosis and individualized treatment.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Medulloblastoma meta-cohort</title><p>We collected data from publications presenting large-scale datasets (<xref ref-type="bibr" rid="bib35">Jones et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">Northcott et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Pugh et al., 2012</xref>; <xref ref-type="bibr" rid="bib70">Robinson et al., 2012</xref>) and two public datasets available online (PBCA-DE and PEME-CA). We retrieved available exome sequencing profiles as well as copy number alterations, gene expression, and clinical data. We translated gene identifiers into gene symbols according to ENSEMBL annotations v.93 and then made sure all the gene symbols are found in the network and are up to date according to GeneCards (<xref ref-type="bibr" rid="bib77">Stelzer et al., 2011</xref>) annotations.</p><p>For consistency with the publication datasets, we excluded the following types of mutations from PBCA-DE and PEME-CA sets: intron variant, upstream gene variant, 3_prime_UTR_variant, 5_prime_UTR_variant, intergenic region, downstream gene variant, synonymous variant, and splice region variant. For a few patient IDs that were found in more than one dataset, their mutation profiles were merged (if different).</p><p>Overall survival data was collected from the published datasets. A few patients with discrepant data (for instance, ICGC_MB193 was 2.3 years old according to Northcott dataset, but 70 years old according to PBCA-DE dataset) were excluded. For 18 samples with different follow-up, we accepted the newest survival time values from Northcott dataset.</p><p>Data from all the datasets were combined into one cohort dubbed MB(union), so that 541 patients were covered with both clinical and exome sequencing data.</p></sec><sec id="s4-2"><title>TCGA cohorts</title><p>The TCGA data were obtained via <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>. Clinical profiles were used according to the most recent update (<xref ref-type="bibr" rid="bib45">Liu et al., 2019</xref>).</p></sec><sec id="s4-3"><title>Network enrichment analysis</title><p>Network enrichment between two gene sets of interest S<sub>a</sub> and S<sub>b</sub> is estimated by comparing the actual number of network edges <inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo stretchy="false">↔</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> that connect nodes of S<sub>a</sub> with nodes of S<sub>b</sub> in the real, biological network <italic>G<sub>B</sub></italic>=(<italic>E</italic>,<italic>V</italic>) with a number expected by chance <inline-formula><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo stretchy="false">↔</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> in a random network <italic>G<sub>R</sub></italic>=(<italic>E</italic>,<italic>V</italic>) where particular node degrees <italic>k</italic> of genes <inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">∀</mml:mi><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">S</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">a</mml:mi></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:mtext> </mml:mtext><mml:mi mathvariant="normal">∀</mml:mi><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">S</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">b</mml:mi></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:mtext> </mml:mtext><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>≠</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:msub><mml:mi>g</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> equal to those of the actual network (which implicitly assumes that the whole degree sequences of <italic>G<sub>B</sub></italic> and <italic>G<sub>R</sub></italic> are identical, too). In an earlier work (<xref ref-type="bibr" rid="bib3">Alexeyenko et al., 2012</xref>), series of randomized instances of <italic>G<sub>R</sub></italic> were created using an algorithm of explicit edge permutation (<xref ref-type="bibr" rid="bib50">Maslov and Sneppen, 2002</xref>) and used for estimating expected variance of <italic>ε</italic>. Later, it was demonstrated (<xref ref-type="bibr" rid="bib33">Jeggari and Alexeyenko, 2017</xref>) that <inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mover><mml:msub><mml:mi>ϵ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">↔</mml:mo><mml:mi>G</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> can be calculated analytically in a fast and unbiased manner:<disp-formula id="equ4"><mml:math id="m4"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo stretchy="false">↔</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:munderover><mml:msub><mml:mtext>k</mml:mtext><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:munderover><mml:msub><mml:mtext>k</mml:mtext><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mtext>E </mml:mtext><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mo>;</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Then the difference between the actual and expected edge counts<disp-formula id="equ5"><mml:math id="m5"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">↔</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">↔</mml:mo><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>;</mml:mo></mml:mrow></mml:math></disp-formula></p><p>is used to estimate significance of the relation <inline-formula><mml:math id="inf9"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo>↔</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> with a <italic>χ</italic>2 statistic:<disp-formula id="equ6"><mml:math id="m6"><mml:mrow><mml:msup><mml:mrow><mml:mi>χ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:msubsup><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo stretchy="false">↔</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:msup><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo stretchy="false">↔</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>The <italic>χ</italic>2 does not follow Gaussian distribution, but it can be conveniently converted to Z-scores and then used safely for downstream calculations in for example linear models.</p><p>In the simplest NEA case one of the sets is a single gene <italic>i</italic>:<disp-formula id="equ7"><mml:math id="m7"><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">↔</mml:mo><mml:mrow><mml:mi mathvariant="bold">S</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>g</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">Δ</mml:mi><mml:msub><mml:mi>ε</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">↔</mml:mo><mml:mrow><mml:mi mathvariant="bold">S</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">↔</mml:mo><mml:mrow><mml:mi mathvariant="bold">S</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>;</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ8"><mml:math id="m8"><mml:mrow><mml:msup><mml:mrow><mml:mi>χ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:msubsup><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">↔</mml:mo><mml:mrow><mml:mi mathvariant="bold">S</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi></mml:mrow><mml:msubsup><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow><mml:mtext>E </mml:mtext><mml:mrow><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mover><mml:mi>ε</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo stretchy="false">↔</mml:mo><mml:mrow><mml:mi mathvariant="bold">S</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>which simplified calculation and – within this work – enabled estimation of network enrichment for a mutated gene against the (rest of) mutations in the same cancer genome, called mutated gene set (MGS) in MutSet method or functional gene set (FGS, or simply pathways) in case of PathReg.</p></sec><sec id="s4-4"><title>Network</title><p>For NEA we merged network of top 1 million edges, ranked by confidence (i.e. Final Bayesian Score) from FunCoup 3 (<xref ref-type="bibr" rid="bib74">Schmitt et al., 2014</xref>) and all edges of Pathway Commons 9 (<xref ref-type="bibr" rid="bib14">Cerami et al., 2010</xref>; <xref ref-type="bibr" rid="bib71">Rodchenkov et al., 2020</xref>). We made sure that all genes reported as altered in at least one of the ten cancer cohorts had up-to-date gene symbols in network. That resulted in a network of 19,035 nodes (unique gene symbols) connected with 1,731,648 unique edges.</p></sec><sec id="s4-5"><title>Mutation gene sets and driver gene sets</title><p>We defined mutated gene sets (MGS) as lists of all genes of a given tumour sample reported with somatic mutations (SM) in the MAF files. MGSs were used as whole sets in driver evaluation of MutSet channel. MGSs <bold><italic>did not include</italic></bold> copy number altered (CNA) genes.</p><p>The analysis included all mutations reported in the TCGA MAF files, regardless of predicted functional impact. Indeed, although synonymous and intronic mutations were often disregarded in cancer research, their involvement in carcinogenesis seems likely and has been recently demonstrated (<xref ref-type="bibr" rid="bib75">Sharma et al., 2019</xref>). In our datasets, frequency of silent mutations was somewhat lower than of non-synonymous ones, but still significant so that many frequently mutated genes showed elevated rates in both categories (<xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>). Therefore, each altered gene <italic>i</italic> from a given sample, either SM or CNA, was evaluated against the MGS and received a MutSet q-value. Significantly altered genes with were included in final driver gene sets DGS<sub>0.05</sub> and DGS<sub>0.01</sub> under conditions <italic>q(MutSet&amp;PathReg</italic>)&lt;0.05 and <italic>q(MutSet&amp;PathReg</italic>)&lt;0.01, respectively.</p></sec><sec id="s4-6"><title>Functional gene sets</title><p>For the PathReg predictor, we used 318 KEGG pathways from version as of 16 August 2018. Considering the importance of SHH and WNT pathways in e.g. medulloblastoma, alongside with respective KEGG pathways we included these two also in Biocarta (<xref ref-type="bibr" rid="bib54">Nishimura, 2001</xref>) versions (the versions were very different in size and length). We updated gene symbols in the sets in the same way as described for the mutations above.</p><p>For the survival analysis, the FGS collection consisted of 1,659 entries from BioCarta (<xref ref-type="bibr" rid="bib54">Nishimura, 2001</xref>), KEGG (<xref ref-type="bibr" rid="bib37">Kanehisa et al., 2002</xref>), Reactome (<xref ref-type="bibr" rid="bib17">Croft et al., 2014</xref>), WikiPathways (<xref ref-type="bibr" rid="bib62">Pico et al., 2008</xref>), MetaCyc (<xref ref-type="bibr" rid="bib12">Caspi et al., 2014</xref>), and MSigDB hallmarks (<xref ref-type="bibr" rid="bib43">Liberzon et al., 2015</xref>).</p></sec><sec id="s4-7"><title>Altered gene sets (transcriptomics)</title><p>The gene expression data was used from the available cohort data sets:</p><list list-type="bullet"><list-item><p>Affymetrix for MB (<xref ref-type="bibr" rid="bib70">Robinson et al., 2012</xref>);</p></list-item><list-item><p>Agilent for OV and GBM;</p></list-item><list-item><p>IlluminaHiSeq_RNASeqV2 for the rest of TCGA cohorts.</p></list-item></list><p>The AGS were compiled as sample-specific lists of top <italic>N</italic> genes (<italic>N</italic>=[50,100,200]) with normalized mRNA expression most different from the respective cohort mean using function samples2ags(…, method = &quot;topnorm&quot;) from R package NEArender (<xref ref-type="bibr" rid="bib33">Jeggari and Alexeyenko, 2017</xref>).</p></sec><sec id="s4-8"><title>NEAdriver: algorithm</title><p>The driver discovery algorithm combined results from two NEA-based channels, MutSet and PathReg.</p></sec><sec id="s4-9"><title>MutSet channel</title><p>The MutSet values quantified network enrichment between each gene <italic>m</italic> having a somatic point mutation in genome <italic>j</italic> and the set MGS of all other point mutations in the same genome (<italic>m</italic> ∈ <italic>MGS<sub>j</sub></italic>). They were calculated as NEA scores <inline-formula><mml:math id="inf10"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi><mml:mo>↔</mml:mo><mml:mi>M</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> so that within a cohort the same gene might receive multiple, sample-specific MutSet values. Respective p-values were obtained from the normally distributed <inline-formula><mml:math id="inf11"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi><mml:mo>↔</mml:mo><mml:mi>M</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> values with a trivial R function pnorm (<xref ref-type="bibr" rid="bib33">Jeggari and Alexeyenko, 2017</xref>).</p></sec><sec id="s4-10"><title>PathReg channel</title><p>As the independent variable for training the PathReg predictor, we employed vectors anchor.summary. Specific NEA scores were calculated for every gene <italic>i</italic> present in the network (N=19035) versus every MGS in the given cancer cohort <italic>c</italic>. The anchor.summary values <italic>µ<sub>ic</sub></italic> were then obtained by summing up over all <italic>N<sub>c</sub></italic> available samples, regardless of mutation status of <italic>i</italic> in genome <italic>j</italic>:<disp-formula id="equ9">;<mml:math id="m9"><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:mrow><mml:mi mathvariant="normal">log</mml:mi></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>i</mml:mi><mml:mo>↔</mml:mo><mml:mi>M</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:msqrt></mml:math></disp-formula></p><p>Since the score <inline-formula><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>i</mml:mi><mml:mo>↔</mml:mo><mml:mi>M</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> is derived from the network patterns of mutated genes across the cohort and does not depend on the mutation profile of <italic>i</italic> itself, the <italic>µ<sub>ic</sub></italic> value would reflect a general propensity of <italic>i</italic> to interact with constellations of putative cancer genes. We note that the algorithm is not given any information on previously identified cancer driver genes and works in the assumption that passenger mutations would not produce relevant signal. The transformations via <inline-formula><mml:math id="inf13"><mml:mi>χ</mml:mi><mml:mn>2</mml:mn><mml:mo>→</mml:mo><mml:mi mathvariant="normal">Z</mml:mi></mml:math></inline-formula>, log, and square root were imposed in order to render distributions closer to Gaussian.</p><p>The <italic>µ<sub>ic</sub></italic> profiles were rather scarce due to rare occurrence in MGS of true drivers that would interact with a given gene <italic>i</italic>. We thus further improved the gene specific values via modeling <italic>µ<sub>ic</sub></italic> with pathway NEA scores <inline-formula><mml:math id="inf14"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>↔</mml:mo><mml:mi>F</mml:mi><mml:mi>G</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . These were calculated for 320 FGS versus each of the <italic>N</italic> network genes and then used as a matrix of dependent variables <bold>Φ</bold> in PathReg training.</p><p>Then sparse regression models were created using function cv.glmnet from R package glmnet (<xref ref-type="bibr" rid="bib24">Friedman et al., 2010</xref>).The chosen package implements elastic net models for solving the problem:<disp-formula id="equ10">,<mml:math id="m10"><mml:mrow><mml:mrow><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:munder></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>l</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi></mml:mrow></mml:mfenced><mml:msubsup><mml:mrow><mml:mfenced close="‖" open="‖" separators="|"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mi>α</mml:mi><mml:msub><mml:mrow><mml:mfenced close="‖" open="‖" separators="|"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>where α is a mixing parameter for balance between lasso and ridge regression (whereby <italic>α</italic>=0 and <italic>α</italic>=1 would lead to plain ridge and lasso regressions, respectively). In our case (<italic>α</italic>=1), glmnet solved just the lasso problem:<disp-formula id="equ11"><mml:math id="m11"><mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:munder></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>λ</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:munder><mml:mrow><mml:mi mathvariant="normal">min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>β</mml:mi></mml:mrow></mml:munder></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mi>Φ</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:msub><mml:mrow><mml:mfenced close="‖" open="‖" separators="|"><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Parameter λ determines complexity of the multivariate regression model, i.e. what subset of initially submitted variables of <bold>Φ</bold> should receive non-zero coefficients. Under 3-fold cross-validation, function cv.glmnet tested a series of λ values while controlling the cross-validation mean squared error (CVM). The cohort-specific optimum <italic>λ<sub>с</sub></italic> was found as a trade-off between model precision and complexity using Bayesian information criterion (BIC), which was deemed preferable (<xref ref-type="bibr" rid="bib26">Giraud, 2015</xref>) over Akaike information criterion in the context of favourable dimensionality <inline-formula><mml:math id="inf15"><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>≫</mml:mo><mml:mi>p</mml:mi><mml:mo>;</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>320</mml:mn><mml:mo>)</mml:mo></mml:math></inline-formula>. The optimal <italic>λ<sub>с</sub></italic> was set at the number of FGS variables with non-zero coefficients <italic>k</italic> as the smallest possible within 2 standard errors of BIC from the lowest BIC value:<disp-formula id="equ12"><mml:math id="m12"><mml:mrow><mml:mi>k</mml:mi><mml:mo>:</mml:mo><mml:mtext> </mml:mtext><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:mrow><mml:mi>λ</mml:mi></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>B</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi><mml:mo>&lt;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mo form="prefix" movablelimits="true">inf</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>B</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>B</mml:mi><mml:mi>I</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:msqrt><mml:mi>n</mml:mi></mml:msqrt></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>;</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="equ13"><mml:math id="m13"><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">∀</mml:mi><mml:mi>f</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mo>;</mml:mo><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>β</mml:mi><mml:mo>∋</mml:mo><mml:mi>β</mml:mi><mml:mo>≠</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo>;</mml:mo></mml:mrow></mml:math></disp-formula></p><p>After this training and model selection step, the retained test subsets were used to check how the original values <italic>µ<sub>ic</sub></italic> correlate with the predicted values <italic>m<sub>ic</sub></italic> (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><p>The distribution of <italic>m<sub>ic</sub></italic> values was non-parametric but close to Gaussian. Therefore, respective p-values were modelled via a normal distribution where mean and standard deviation were estimated as median and 84.2<sup>th</sup> percentile of the empirical distribution, respectively:<disp-formula id="equ14"><mml:math id="m14"><mml:mover accent="true"><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mo>~</mml:mo></mml:mover><mml:mo>;</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">σ</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mn>84.2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>(in the Gaussian distribution 84.2% of values are within <inline-formula><mml:math id="inf16"><mml:mover accent="true"><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mo>-</mml:mo></mml:mover><mml:mo>±</mml:mo><mml:mi mathvariant="normal">σ</mml:mi></mml:math></inline-formula>).</p></sec><sec id="s4-11"><title>Integration of channels</title><p>The p- values from both MutSet and PathReg were adjusted to with Benjamini-Hochberg method (<xref ref-type="bibr" rid="bib7">Benjamini and Hochberg, 1995</xref>). These <italic>q-</italic>values were equivalent to false discovery rate which conveys the probability of a given driver prediction to be false. These values were integrated into the final value as a product <italic>q(MutSet&amp;PathReg</italic>)=<italic>q</italic><sub>MutSet</sub>*<italic>q</italic><sub>PathReg</sub>, which presented the probability that neither channel have produced true predictions. Therefore, 1 – <italic>q(MutSet&amp;PathReg</italic>) was the probability of either channel to be true and we convened to trust a driver prediction if <italic>q(MutSet&amp;PathReg</italic>)&lt;<italic>c</italic> (<italic>c</italic>=[0.01, 0.05]).</p></sec><sec id="s4-12"><title>Gold standard and alternative driver sets</title><sec id="s4-12-1"><title>Literature-based sets</title><p>As gold standard for <bold>MB</bold>, we compiled a list of unique 516 gene symbols (Hg19 human genome version), of which 12 were found in OMIM database, 140 in Disease Ontology, and 399 in MB-related publications found in PubMed:</p><list list-type="bullet"><list-item><p>Cavalli, F. M. G. et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. <italic>Cancer Cell</italic> <bold>31</bold>, 737–754.e6 (2017).</p></list-item><list-item><p>Ellison, D. W. et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. <italic>Acta Neuropathol. (Berl</italic>.) <bold>121</bold>, 381–396 (2011).</p></list-item><list-item><p>Gajjar, A. et al. Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. <italic>J. Clin. Oncol</italic>. <bold>33</bold>, 2986–2998 (2015).</p></list-item><list-item><p>Hovestadt, V. et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. <italic>Nature</italic> <bold>510</bold>, 537–541 (2014).</p></list-item><list-item><p>Jones, D. T. W. et al. Dissecting the genomic complexity underlying medulloblastoma. <italic>Nature</italic> <bold>488</bold>, 100–105 (2012).</p></list-item><list-item><p>Northcott, P. A. et al. Medulloblastomics: the end of the beginning. <italic>Nat. Rev. Cancer</italic> <bold>12</bold>, 818–834 (2012).</p></list-item><list-item><p>Northcott, P. A. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <italic>Nature</italic> <bold>488</bold>, 49–56 (2012).</p></list-item><list-item><p>Northcott, P. A., Dubuc, A. M., Pfister, S. &amp; Taylor, M. D. Molecular subgroups of medulloblastoma. <italic>Expert Rev. Neurother</italic>. <bold>12</bold>, 871–884 (2012).</p></list-item><list-item><p>Parsons, D. W. et al. The genetic landscape of the childhood cancer medulloblastoma. <italic>Science</italic> <bold>331</bold>, 435–439 (2011).</p></list-item><list-item><p>Pugh, T. J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. <italic>Nature</italic> <bold>488</bold>, 106–110 (2012).</p></list-item><list-item><p>Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. <italic>Nature</italic> <bold>488</bold>, 43–48 (2012).</p></list-item><list-item><p>Taylor, M. D. et al. Molecular subgroups of medulloblastoma: the current consensus. <italic>Acta Neuropathol. (Berl</italic>.) <bold>123</bold>, 465–472 (2012).</p></list-item></list><p>We included all altered genes mentioned in these publications. Mechanisms of alteration included changed methylation, gene copy number, and point mutations.</p><p>For the TCGA cohorts, we employed the dedicated KEGG pathways:</p><list list-type="bullet"><list-item><p>BRCA &lt;- hsa05224:Breast_cancer;</p></list-item><list-item><p>GBM &lt;- hsa05214:Glioma;</p></list-item><list-item><p>LUAD &lt;- hsa05223:Non-small_cell_lung_cancer;</p></list-item><list-item><p>LUSC &lt;- hsa05223:Non-small_cell_lung_cancer;</p></list-item><list-item><p>SKCM &lt;- hsa05218:Melanoma;</p></list-item><list-item><p>PRAD &lt;- hsa05215:Prostate_cancer;</p></list-item><list-item><p>PAAD &lt;- hsa05212:Pancreatic_cancer;</p></list-item><list-item><p>COAD &lt;- hsa05210:Colorectal_cancer;</p></list-item><list-item><p>BLCA &lt;- hsa05219:Bladder_cancer;</p></list-item><list-item><p>OV &lt;- hsa05213:Endometrial_cancer, since origins of these two are intertwined (<xref ref-type="bibr" rid="bib52">Merritt and Cramer, 2010</xref>).</p></list-item></list></sec></sec><sec id="s4-13"><title>Gene sets from computational analyses</title><p>Bailey2018.PANCAN, N=200 (<xref ref-type="bibr" rid="bib4">Bailey et al., 2018</xref>) PanCancer and PanSoftware analysis over 9,423 tumor <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/exome">exomes</ext-link> from 33 of The Cancer Genome Atlas projects using 26 computational tools.</p><p>HCD, N=291 (<xref ref-type="bibr" rid="bib81">Tamborero et al., 2013</xref>) discovered drivers in 12 TCGA cohorts (of which six overlapped with our analysis) with a combination of four algorithms that prioritized mutated genes based on mutation rate, functional impact, positional ‘hotspots’, and specific enrichment in phosphorylation sites.</p><p>IntOGen, N=37…73 (<xref ref-type="bibr" rid="bib49">Martínez-Jiménez et al., 2020</xref>) cancer-type-specific lists of cancer genes (per type) predicted by <ext-link ext-link-type="uri" xlink:href="https://www.intogen.org/">Integrative OncoGenomics</ext-link> (IntOGen) pipeline.</p><p>Martincorena-2017, N=369 (<xref ref-type="bibr" rid="bib48">Martincorena et al., 2017</xref>) a list of known cancer genes used in the <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/molecular-evolution">molecular evolution</ext-link> (positive selection) analysis and applied 7664 tumors across 29 cancer types.</p><p>MuSiC, N=127 (<xref ref-type="bibr" rid="bib36">Kandoth et al., 2013</xref>) identified drivers based on relative point mutation frequency, assisted with expression analysis and database annotations in 12 TCGA cancers (of which six overlapped with our analysis). We used the ‘PanCancer’ list.</p><p>MutSig, N=260 (<xref ref-type="bibr" rid="bib41">Lawrence et al., 2015</xref>) performed a comprehensive point mutation frequency analysis using exome sequencing data from 21 cancer cohorts (of which nine overlapped with our study), while accounting for mutation burden, clustering, and functional impact.</p><p>NetSig5000, N=62 (<xref ref-type="bibr" rid="bib30">Horn et al., 2018</xref>) gathered evidence for potential driverness of each gene via functional coupling to frequently mutated genes in the global network. The genes’ own mutation frequencies were incorporated into NetSig scores at a separate step.</p></sec><sec id="s4-14"><title>Database gene sets</title><p>Cancer Gene Census N=12…64 (<xref ref-type="bibr" rid="bib25">Futreal et al., 2004</xref>) cancer type specific lists were downloaded on 7<sup>th</sup> of February, 2019.</p><p>KEGG#05200:Pathways_in_cancer, N=395 (<xref ref-type="bibr" rid="bib37">Kanehisa et al., 2002</xref>) was a ‘pan-cancer’ version including a curated selection of organ-specific cancer pathway gene lists.</p><p>Five ‘general’ cancer pathways, N=457 (<xref ref-type="bibr" rid="bib37">Kanehisa et al., 2002</xref>) was created as a union of the following cancer related KEGG pathways:</p><list list-type="bullet"><list-item><p>hsa05202:Transcriptional_misregulation_in_cancer;</p></list-item><list-item><p>hsa05203:Viral_carcinogenesis;</p></list-item><list-item><p>hsa05204:Chemical_carcinogenesis;</p></list-item><list-item><p>hsa05205:Proteoglycans_in_cancer;</p></list-item><list-item><p>hsa05206:MicroRNAs_in_cancer.</p></list-item></list><p>FoundationOne, N=330 (<ext-link ext-link-type="uri" xlink:href="https://www.foundationmedicine.com/resources">https://www.foundationmedicine.com/resources</ext-link>) is the targeted sequencing panel used for cancer diagnostics, created as a merge of ‘general’ and ‘rearrangements’ sections.</p></sec><sec id="s4-15"><title>Gene sets from individualized analyses</title><p>OncoIMPACT (N=162…695 per cohort) (<xref ref-type="bibr" rid="bib9">Bertrand et al., 2015</xref>) used an expression-driven approach to verify driver roles of point mutations in five TCGA cohorts (of which four overlapped with our analysis). The paper reported cohort-specific driver ranks rather than individual, sample-level estimates. The genes that received a rank were used in comparisons with NEAdriver results.</p><p>SCS (<xref ref-type="bibr" rid="bib28">Guo et al., 2018</xref>) reported driver role evaluation in individual samples. They reported only top 50 genes after global, cohort-specific ranking. In parallel, the tables contained top 50 genes from OncoIMPACT (<xref ref-type="bibr" rid="bib9">Bertrand et al., 2015</xref>), DriverNet (<xref ref-type="bibr" rid="bib6">Bashashati et al., 2012</xref>), DawnRank (<xref ref-type="bibr" rid="bib31">Hou and Ma, 2014</xref>), and HotNet2 (<xref ref-type="bibr" rid="bib67">Reyna et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Leiserson et al., 2015</xref>) methods, which we also imported and used in our comparison.</p></sec><sec id="s4-16"><title>Sets of artefactual driver genes</title><p>Lawrence2013.FPs, N=19 (<xref ref-type="bibr" rid="bib39">Lawrence et al., 2013</xref>) list of genes frequently presented in literature as false positive cancer drivers.</p><p>Martincorena2017.artifacts, N=49 (<xref ref-type="bibr" rid="bib48">Martincorena et al., 2017</xref>) list of genes which are usually heavily-affected by sequencing artifacts.</p><p>IntOGen.KnownArtifacts, N=19 (<xref ref-type="bibr" rid="bib49">Martínez-Jiménez et al., 2020</xref>) list of genes labelled as “Known artifact” in their resulting table.</p></sec><sec id="s4-17"><title>Normalization of mutation frequencies</title><p>The number of samples where each given gene was mutated was normalized by dividing it with its CDS length. When necessary, the sample-specific total mutation burden values were accounted for as total number of point mutations reported in all genes per sample.</p></sec><sec id="s4-18"><title>Code availability</title><p>Documented code is available under the modified BSD license on GitHub: <ext-link ext-link-type="uri" xlink:href="https://github.com/aveviort/NEArender-2.x">https://github.com/aveviort/NEArender-2.x</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:5e5c27611774678e1354f07afeca324e60a3a302;origin=https://github.com/AveViort/NEArender-2.x;visit=swh:1:snp:13bb5c41eec32b4e4d2f9b44ef2b24f9ce1546aa;anchor=swh:1:rev:5829beb819c689790359f199547362a31d1a1d54">swh:1:rev:5829beb819c689790359f199547362a31d1a1d54</ext-link>; <xref ref-type="bibr" rid="bib60">Petrov, 2022</xref>).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Resources, Software, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Funding acquisition, Investigation, Methodology, Software, Supervision, Visualization, Writing – original draft</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Performance of PathReg multiple regression models.</title><p>Observed vs. predicted values of anchor.summary values represents performance of created models on continuous scale. In absence of a strict cut-off, performance was measured as a correlation between anchor.summary observed for each gene in the given cohort versus the a value predicted by the multiple regression model. In heatmaps, values next to gene names indicate number of samples with mutations in the given gene.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-supp1-v2.zip"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Size vs node degree of cancer genes included in NEAdriver driver predictions, compared against the union of all alternative sets.</title><p>X coordinates for the alternative sets represent their sizes. For NEAdriver (which in total, across all cohort samples typically predicted hundreds genes, most being very rare) the sets represent samples n=[50, 100, 200, 400] genes most frequently predicted in each cohort.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-supp2-v2.zip"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Comparison of NEAdriver results with OncoIMPACT (4 cohorts).</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-supp3-v2.zip"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Comparison of NEAdriver results with other network-based methods (4 cohorts, 50 top genes from each method).</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-supp4-v2.zip"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Dependence of NEAdriver q-values from covariates.</title><p>The five pages present relations between MutSet&amp;PathReg q (Y axis) and no. of mutations per cohort, gene length, and normalized mutation frequency, replication rate, and gene expression rates, respectively (X axis). Top left legend: Spearman rank R and Kendall tau represent overall correlations between X and Y coordinates regardless of other factors. Bottom left legend: terms’ significance in 4-way linear models. Colored points: genes suggested as potential artifacts in literature; those receiving q&lt;0.05 are text-labeled.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-supp5-v2.zip"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Kaplan-Meier plots for 10 cohorts: different survival metrics, dichotomized by NEA scores for either DGS or GE AGS.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-supp6-v2.zip"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>No of mutations versus normalized mutation frequency: relative frequencies of silent and non-silent mutations per gene.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-supp7-v2.zip"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Summary tables over each of the ten cohorts.</title><p>PathReg, MutSet, and combined values per sample, per gene, in each cohort. MutSet q-values are accompanied with no. of network links observed between the given gene and point mutations in the sample, as well as respective NEA Z and NEA p-value. All the MutSet values are sample-specific. PathReg q-values are accompanied with respective anchor.summary, PathReg score, and PathReg p-values. All the PathReg values are cohort-specific and not sample-specific. NEAdriver q-value is product of MutSet q-value and PathReg q-value. The last 3 columns indicate genes listed as possible artifacts in literature.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74010-supp8-v2.zip"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-74010-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p><p>The following previously published dataset was used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>TCGA consortium</collab></person-group><year iso-8601-date="2008">2008</year><data-title>The Cancer Genome Atlas</data-title><source>TCGA</source><pub-id pub-id-type="accession" xlink:href="https://www.cancer.gov/tcga">Genome-Atlas</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors are grateful to Vetenskapsrådet for provided funding. The analysis used data generated by the TCGA Research Network: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/tcga">https://www.cancer.gov/tcga</ext-link>.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adzhubei</surname><given-names>IA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Peshkin</surname><given-names>L</given-names></name><name><surname>Ramensky</surname><given-names>VE</given-names></name><name><surname>Gerasimova</surname><given-names>A</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Kondrashov</surname><given-names>AS</given-names></name><name><surname>Sunyaev</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A method and server for predicting damaging missense mutations</article-title><source>Nature Methods</source><volume>7</volume><fpage>248</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1038/nmeth0410-248</pub-id><pub-id pub-id-type="pmid">20354512</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>Riley</surname><given-names>C</given-names></name><name><surname>Rice</surname><given-names>G</given-names></name><name><surname>Quinn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment</article-title><source>Clinical &amp; Experimental Metastasis</source><volume>22</volume><fpage>391</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1007/s10585-005-1262-y</pub-id><pub-id pub-id-type="pmid">16283482</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexeyenko</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Pernemalm</surname><given-names>M</given-names></name><name><surname>Guegan</surname><given-names>J</given-names></name><name><surname>Dessen</surname><given-names>P</given-names></name><name><surname>Lazar</surname><given-names>V</given-names></name><name><surname>Lehtiö</surname><given-names>J</given-names></name><name><surname>Pawitan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Network enrichment analysis: extension of gene-set enrichment analysis to gene networks</article-title><source>BMC Bioinformatics</source><volume>13</volume><elocation-id>226</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-13-226</pub-id><pub-id pub-id-type="pmid">22966941</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>MH</given-names></name><name><surname>Tokheim</surname><given-names>C</given-names></name><name><surname>Porta-Pardo</surname><given-names>E</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>D</given-names></name><name><surname>Weerasinghe</surname><given-names>A</given-names></name><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Reardon</surname><given-names>B</given-names></name><name><surname>Kwok-Shing Ng</surname><given-names>P</given-names></name><name><surname>Jeong</surname><given-names>KJ</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>EM</given-names></name><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Rubio-Perez</surname><given-names>C</given-names></name><name><surname>Nagarajan</surname><given-names>N</given-names></name><name><surname>Cortés-Ciriano</surname><given-names>I</given-names></name><name><surname>Zhou</surname><given-names>DC</given-names></name><name><surname>Liang</surname><given-names>W-W</given-names></name><name><surname>Hess</surname><given-names>JM</given-names></name><name><surname>Yellapantula</surname><given-names>VD</given-names></name><name><surname>Tamborero</surname><given-names>D</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Suphavilai</surname><given-names>C</given-names></name><name><surname>Ko</surname><given-names>JY</given-names></name><name><surname>Khurana</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><collab>MC3 Working Group</collab><collab>Cancer Genome Atlas Research Network</collab><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Godzik</surname><given-names>A</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name><name><surname>Stuart</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>D</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Karchin</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive Characterization of Cancer Driver Genes and Mutations</article-title><source>Cell</source><volume>174</volume><fpage>1034</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.034</pub-id><pub-id pub-id-type="pmid">30096302</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barabási</surname><given-names>AL</given-names></name><name><surname>Gulbahce</surname><given-names>N</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Network medicine: a network-based approach to human disease</article-title><source>Nature Reviews. Genetics</source><volume>12</volume><fpage>56</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/nrg2918</pub-id><pub-id pub-id-type="pmid">21164525</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashashati</surname><given-names>A</given-names></name><name><surname>Haffari</surname><given-names>G</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Ha</surname><given-names>G</given-names></name><name><surname>Lui</surname><given-names>K</given-names></name><name><surname>Rosner</surname><given-names>J</given-names></name><name><surname>Huntsman</surname><given-names>DG</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Aparicio</surname><given-names>SA</given-names></name><name><surname>Shah</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer</article-title><source>Genome Biology</source><volume>13</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2012-13-12-r124</pub-id><pub-id pub-id-type="pmid">23383675</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title><source>Journal of the Royal Statistical Society</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>AC</given-names></name><name><surname>Korkut</surname><given-names>A</given-names></name><name><surname>Kanchi</surname><given-names>RS</given-names></name><name><surname>Hegde</surname><given-names>AM</given-names></name><name><surname>Lenoir</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Ravikumar</surname><given-names>V</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Schultz</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sumazin</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>C</given-names></name><name><surname>Mestdagh</surname><given-names>P</given-names></name><name><surname>Gunaratne</surname><given-names>PH</given-names></name><name><surname>Yau</surname><given-names>C</given-names></name><name><surname>Bowlby</surname><given-names>R</given-names></name><name><surname>Robertson</surname><given-names>AG</given-names></name><name><surname>Tiezzi</surname><given-names>DG</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Godwin</surname><given-names>AK</given-names></name><name><surname>Kuderer</surname><given-names>NM</given-names></name><name><surname>Rader</surname><given-names>JS</given-names></name><name><surname>Zuna</surname><given-names>RE</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Ojesina</surname><given-names>AI</given-names></name><name><surname>Adebamowo</surname><given-names>C</given-names></name><name><surname>Adebamowo</surname><given-names>SN</given-names></name><name><surname>Baggerly</surname><given-names>KA</given-names></name><name><surname>Chen</surname><given-names>T-W</given-names></name><name><surname>Chiu</surname><given-names>H-S</given-names></name><name><surname>Lefever</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>MacKenzie</surname><given-names>K</given-names></name><name><surname>Orsulic</surname><given-names>S</given-names></name><name><surname>Roszik</surname><given-names>J</given-names></name><name><surname>Shelley</surname><given-names>CS</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Vellano</surname><given-names>CP</given-names></name><name><surname>Wentzensen</surname><given-names>N</given-names></name><collab>Cancer Genome Atlas Research Network</collab><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Levine</surname><given-names>DA</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers</article-title><source>Cancer Cell</source><volume>33</volume><fpage>690</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.014</pub-id><pub-id pub-id-type="pmid">29622464</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>D</given-names></name><name><surname>Chng</surname><given-names>KR</given-names></name><name><surname>Sherbaf</surname><given-names>FG</given-names></name><name><surname>Kiesel</surname><given-names>A</given-names></name><name><surname>Chia</surname><given-names>BKH</given-names></name><name><surname>Sia</surname><given-names>YY</given-names></name><name><surname>Huang</surname><given-names>SK</given-names></name><name><surname>Hoon</surname><given-names>DSB</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Hillmer</surname><given-names>A</given-names></name><name><surname>Nagarajan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e44</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gku1393</pub-id><pub-id pub-id-type="pmid">25572314</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bretaud</surname><given-names>S</given-names></name><name><surname>Guillon</surname><given-names>E</given-names></name><name><surname>Karppinen</surname><given-names>SM</given-names></name><name><surname>Pihlajaniemi</surname><given-names>T</given-names></name><name><surname>Ruggiero</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Collagen XV, a multifaceted multiplexin present across tissues and species</article-title><source>Matrix Biology Plus</source><volume>6–7</volume><elocation-id>100023</elocation-id><pub-id pub-id-type="doi">10.1016/j.mbplus.2020.100023</pub-id><pub-id pub-id-type="pmid">33543021</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Jennings</surname><given-names>JL</given-names></name><name><surname>Stein</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer analysis of whole genomes</article-title><source>Nature</source><volume>578</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1969-6</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caspi</surname><given-names>R</given-names></name><name><surname>Altman</surname><given-names>T</given-names></name><name><surname>Billington</surname><given-names>R</given-names></name><name><surname>Dreher</surname><given-names>K</given-names></name><name><surname>Foerster</surname><given-names>H</given-names></name><name><surname>Fulcher</surname><given-names>CA</given-names></name><name><surname>Holland</surname><given-names>TA</given-names></name><name><surname>Keseler</surname><given-names>IM</given-names></name><name><surname>Kothari</surname><given-names>A</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Krummenacker</surname><given-names>M</given-names></name><name><surname>Latendresse</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>LA</given-names></name><name><surname>Ong</surname><given-names>Q</given-names></name><name><surname>Paley</surname><given-names>S</given-names></name><name><surname>Subhraveti</surname><given-names>P</given-names></name><name><surname>Weaver</surname><given-names>DS</given-names></name><name><surname>Weerasinghe</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Karp</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D459</fpage><lpage>D471</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1103</pub-id><pub-id pub-id-type="pmid">24225315</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cava</surname><given-names>C</given-names></name><name><surname>Bertoli</surname><given-names>G</given-names></name><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Olsen</surname><given-names>C</given-names></name><name><surname>Bontempi</surname><given-names>G</given-names></name><name><surname>Castiglioni</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Integration of multiple networks and pathways identifies cancer driver genes in pan-cancer analysis</article-title><source>BMC Genomics</source><volume>19</volume><elocation-id>223</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-017-4423-x</pub-id><pub-id pub-id-type="pmid">5756345</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>EG</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Demir</surname><given-names>E</given-names></name><name><surname>Rodchenkov</surname><given-names>I</given-names></name><name><surname>Babur</surname><given-names>O</given-names></name><name><surname>Anwar</surname><given-names>N</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pathway Commons, a web resource for biological pathway data</article-title><source>Nucleic Acids Research</source><volume>39</volume><fpage>D685</fpage><lpage>D690</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1039</pub-id><pub-id pub-id-type="pmid">21071392</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Compact Integration of Multi-Network Topology for Functional Analysis of Genes</article-title><source>Cell Systems</source><volume>3</volume><fpage>540</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2016.10.017</pub-id><pub-id pub-id-type="pmid">27889536</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciriello</surname><given-names>G</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mutual exclusivity analysis identifies oncogenic network modules</article-title><source>Genome Research</source><volume>22</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1101/gr.125567.111</pub-id><pub-id pub-id-type="pmid">21908773</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croft</surname><given-names>D</given-names></name><name><surname>Mundo</surname><given-names>AF</given-names></name><name><surname>Haw</surname><given-names>R</given-names></name><name><surname>Milacic</surname><given-names>M</given-names></name><name><surname>Weiser</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Caudy</surname><given-names>M</given-names></name><name><surname>Garapati</surname><given-names>P</given-names></name><name><surname>Gillespie</surname><given-names>M</given-names></name><name><surname>Kamdar</surname><given-names>MR</given-names></name><name><surname>Jassal</surname><given-names>B</given-names></name><name><surname>Jupe</surname><given-names>S</given-names></name><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>May</surname><given-names>B</given-names></name><name><surname>Palatnik</surname><given-names>S</given-names></name><name><surname>Rothfels</surname><given-names>K</given-names></name><name><surname>Shamovsky</surname><given-names>V</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name><name><surname>Stein</surname><given-names>L</given-names></name><name><surname>D’Eustachio</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The Reactome pathway knowledgebase</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D472</fpage><lpage>D477</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1102</pub-id><pub-id pub-id-type="pmid">24243840</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dees</surname><given-names>ND</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Schierding</surname><given-names>W</given-names></name><name><surname>Koboldt</surname><given-names>DC</given-names></name><name><surname>Mooney</surname><given-names>TB</given-names></name><name><surname>Callaway</surname><given-names>MB</given-names></name><name><surname>Dooling</surname><given-names>D</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MuSiC: identifying mutational significance in cancer genomes</article-title><source>Genome Research</source><volume>22</volume><fpage>1589</fpage><lpage>1598</lpage><pub-id pub-id-type="doi">10.1101/gr.134635.111</pub-id><pub-id pub-id-type="pmid">22759861</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Kacprowski</surname><given-names>T</given-names></name><name><surname>Albrecht</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Recent approaches to the prioritization of candidate disease genes</article-title><source>Wiley Interdisciplinary Reviews. Systems Biology and Medicine</source><volume>4</volume><fpage>429</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1002/wsbm.1177</pub-id><pub-id pub-id-type="pmid">22689539</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erten</surname><given-names>S</given-names></name><name><surname>Bebek</surname><given-names>G</given-names></name><name><surname>Ewing</surname><given-names>RM</given-names></name><name><surname>Koyutürk</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>DADA: Degree-Aware Algorithms for Network-Based Disease Gene Prioritization</article-title><source>BioData Mining</source><volume>4</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.1186/1756-0381-4-19</pub-id><pub-id pub-id-type="pmid">21699738</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The “dnet” approach promotes emerging research on cancer patient survival</article-title><source>Genome Medicine</source><volume>6</volume><elocation-id>64</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-014-0064-8</pub-id><pub-id pub-id-type="pmid">25246945</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>M</given-names></name><name><surname>Jeggari</surname><given-names>A</given-names></name><name><surname>Peuget</surname><given-names>S</given-names></name><name><surname>Böttger</surname><given-names>F</given-names></name><name><surname>Selivanova</surname><given-names>G</given-names></name><name><surname>Alexeyenko</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Prediction of response to anti-cancer drugs becomes robust via network integration of molecular data</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>2379</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-39019-2</pub-id><pub-id pub-id-type="pmid">30787419</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freudenberg</surname><given-names>J</given-names></name><name><surname>Propping</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A similarity-based method for genome-wide prediction of disease-relevant human genes</article-title><source>Bioinformatics (Oxford, England)</source><volume>18 Suppl 2</volume><fpage>S110</fpage><lpage>S115</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/18.suppl_2.s110</pub-id><pub-id pub-id-type="pmid">12385992</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JH</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regularization Paths for Generalized Linear Models via Coordinate Descent</article-title><source>Journal of Statistical Software</source><volume>33</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.18637/jss.v033.i01</pub-id><pub-id pub-id-type="pmid">20808728</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Coin</surname><given-names>L</given-names></name><name><surname>Marshall</surname><given-names>M</given-names></name><name><surname>Down</surname><given-names>T</given-names></name><name><surname>Hubbard</surname><given-names>T</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A census of human cancer genes</article-title><source>Nature Reviews Cancer</source><volume>4</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/nrc1299</pub-id><pub-id pub-id-type="pmid">14993899</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Giraud</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><source>Introduction to High-Dimensional Statistics</source><publisher-loc>Florida, United States</publisher-loc><publisher-name>CRC Press</publisher-name></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnad</surname><given-names>F</given-names></name><name><surname>Baucom</surname><given-names>A</given-names></name><name><surname>Mukhyala</surname><given-names>K</given-names></name><name><surname>Manning</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Assessment of computational methods for predicting the effects of missense mutations in human cancers</article-title><source>BMC Genomics</source><volume>14 Suppl 3</volume><elocation-id>S7</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-14-S3-S7</pub-id><pub-id pub-id-type="pmid">23819521</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W-F</given-names></name><name><surname>Zhang</surname><given-names>S-W</given-names></name><name><surname>Liu</surname><given-names>L-L</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>Q-Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Discovering personalized driver mutation profiles of single samples in cancer by network control strategy</article-title><source>Bioinformatics (Oxford, England)</source><volume>34</volume><fpage>1893</fpage><lpage>1903</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty006</pub-id><pub-id pub-id-type="pmid">29329368</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>H</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Chouinard</surname><given-names>CR</given-names></name><name><surname>Shrestha</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>JX</given-names></name><name><surname>Worstell</surname><given-names>E</given-names></name><name><surname>Shea</surname><given-names>E</given-names></name><name><surname>Ilic</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kamburov</surname><given-names>A</given-names></name><name><surname>Kashani</surname><given-names>A</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Campbell</surname><given-names>JD</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Lage</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>NetSig: network-based discovery from cancer genomes</article-title><source>Nature Methods</source><volume>15</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4514</pub-id><pub-id pub-id-type="pmid">29200198</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>JP</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>DawnRank: discovering personalized driver genes in cancer</article-title><source>Genome Medicine</source><volume>6</volume><elocation-id>56</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-014-0056-8</pub-id><pub-id pub-id-type="pmid">25177370</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>JPA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Why most published research findings are false</article-title><source>PLOS Medicine</source><volume>2</volume><elocation-id>e124</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0020124</pub-id><pub-id pub-id-type="pmid">16060722</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeggari</surname><given-names>A</given-names></name><name><surname>Alexeyenko</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>NEArender: an R package for functional interpretation of “omics” data via network enrichment analysis</article-title><source>BMC Bioinformatics</source><volume>18</volume><elocation-id>118</elocation-id><pub-id pub-id-type="doi">10.1186/s12859-017-1534-y</pub-id><pub-id pub-id-type="pmid">28361684</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Sanchez</surname><given-names>G</given-names></name><name><surname>Childs</surname><given-names>B</given-names></name><name><surname>Valle</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Human disease genes</article-title><source>Nature</source><volume>409</volume><fpage>853</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1038/35057050</pub-id><pub-id pub-id-type="pmid">11237009</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Jäger</surname><given-names>N</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Zichner</surname><given-names>T</given-names></name><name><surname>Hutter</surname><given-names>B</given-names></name><name><surname>Sultan</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>Y-J</given-names></name><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Hovestadt</surname><given-names>V</given-names></name><name><surname>Stütz</surname><given-names>AM</given-names></name><name><surname>Rausch</surname><given-names>T</given-names></name><name><surname>Warnatz</surname><given-names>H-J</given-names></name><name><surname>Ryzhova</surname><given-names>M</given-names></name><name><surname>Bender</surname><given-names>S</given-names></name><name><surname>Sturm</surname><given-names>D</given-names></name><name><surname>Pleier</surname><given-names>S</given-names></name><name><surname>Cin</surname><given-names>H</given-names></name><name><surname>Pfaff</surname><given-names>E</given-names></name><name><surname>Sieber</surname><given-names>L</given-names></name><name><surname>Wittmann</surname><given-names>A</given-names></name><name><surname>Remke</surname><given-names>M</given-names></name><name><surname>Witt</surname><given-names>H</given-names></name><name><surname>Hutter</surname><given-names>S</given-names></name><name><surname>Tzaridis</surname><given-names>T</given-names></name><name><surname>Weischenfeldt</surname><given-names>J</given-names></name><name><surname>Raeder</surname><given-names>B</given-names></name><name><surname>Avci</surname><given-names>M</given-names></name><name><surname>Amstislavskiy</surname><given-names>V</given-names></name><name><surname>Zapatka</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>UD</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Lasitschka</surname><given-names>B</given-names></name><name><surname>Bartholomae</surname><given-names>CC</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>von Kalle</surname><given-names>C</given-names></name><name><surname>Ast</surname><given-names>V</given-names></name><name><surname>Lawerenz</surname><given-names>C</given-names></name><name><surname>Eils</surname><given-names>J</given-names></name><name><surname>Kabbe</surname><given-names>R</given-names></name><name><surname>Benes</surname><given-names>V</given-names></name><name><surname>van Sluis</surname><given-names>P</given-names></name><name><surname>Koster</surname><given-names>J</given-names></name><name><surname>Volckmann</surname><given-names>R</given-names></name><name><surname>Shih</surname><given-names>D</given-names></name><name><surname>Betts</surname><given-names>MJ</given-names></name><name><surname>Russell</surname><given-names>RB</given-names></name><name><surname>Coco</surname><given-names>S</given-names></name><name><surname>Tonini</surname><given-names>GP</given-names></name><name><surname>Schüller</surname><given-names>U</given-names></name><name><surname>Hans</surname><given-names>V</given-names></name><name><surname>Graf</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>Y-J</given-names></name><name><surname>Monoranu</surname><given-names>C</given-names></name><name><surname>Roggendorf</surname><given-names>W</given-names></name><name><surname>Unterberg</surname><given-names>A</given-names></name><name><surname>Herold-Mende</surname><given-names>C</given-names></name><name><surname>Milde</surname><given-names>T</given-names></name><name><surname>Kulozik</surname><given-names>AE</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>Witt</surname><given-names>O</given-names></name><name><surname>Maass</surname><given-names>E</given-names></name><name><surname>Rössler</surname><given-names>J</given-names></name><name><surname>Ebinger</surname><given-names>M</given-names></name><name><surname>Schuhmann</surname><given-names>MU</given-names></name><name><surname>Frühwald</surname><given-names>MC</given-names></name><name><surname>Hasselblatt</surname><given-names>M</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Rutkowski</surname><given-names>S</given-names></name><name><surname>von Bueren</surname><given-names>AO</given-names></name><name><surname>Williamson</surname><given-names>D</given-names></name><name><surname>Clifford</surname><given-names>SC</given-names></name><name><surname>McCabe</surname><given-names>MG</given-names></name><name><surname>Collins</surname><given-names>VP</given-names></name><name><surname>Wolf</surname><given-names>S</given-names></name><name><surname>Wiemann</surname><given-names>S</given-names></name><name><surname>Lehrach</surname><given-names>H</given-names></name><name><surname>Brors</surname><given-names>B</given-names></name><name><surname>Scheurlen</surname><given-names>W</given-names></name><name><surname>Felsberg</surname><given-names>J</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Yaspo</surname><given-names>M-L</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Korshunov</surname><given-names>A</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dissecting the genomic complexity underlying medulloblastoma</article-title><source>Nature</source><volume>488</volume><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nature11284</pub-id><pub-id pub-id-type="pmid">22832583</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>McLellan</surname><given-names>MD</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>McMichael</surname><given-names>JF</given-names></name><name><surname>Wyczalkowski</surname><given-names>MA</given-names></name><name><surname>Leiserson</surname><given-names>MDM</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Welch</surname><given-names>JS</given-names></name><name><surname>Walter</surname><given-names>MJ</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Ley</surname><given-names>TJ</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational landscape and significance across 12 major cancer types</article-title><source>Nature</source><volume>502</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature12634</pub-id><pub-id pub-id-type="pmid">24132290</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Kawashima</surname><given-names>S</given-names></name><name><surname>Nakaya</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The KEGG databases at GenomeNet</article-title><source>Nucleic Acids Research</source><volume>30</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1093/nar/30.1.42</pub-id><pub-id pub-id-type="pmid">11752249</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Köhler</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Horn</surname><given-names>D</given-names></name><name><surname>Robinson</surname><given-names>PN</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Walking the interactome for prioritization of candidate disease genes</article-title><source>American Journal of Human Genetics</source><volume>82</volume><fpage>949</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2008.02.013</pub-id><pub-id pub-id-type="pmid">18371930</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Stojanov</surname><given-names>P</given-names></name><name><surname>Polak</surname><given-names>P</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Mermel</surname><given-names>CH</given-names></name><name><surname>Roberts</surname><given-names>SA</given-names></name><name><surname>Kiezun</surname><given-names>A</given-names></name><name><surname>Hammerman</surname><given-names>PS</given-names></name><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Drier</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Ramos</surname><given-names>AH</given-names></name><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Helman</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Ambrogio</surname><given-names>L</given-names></name><name><surname>Nickerson</surname><given-names>E</given-names></name><name><surname>Shefler</surname><given-names>E</given-names></name><name><surname>Cortés</surname><given-names>ML</given-names></name><name><surname>Auclair</surname><given-names>D</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Voet</surname><given-names>D</given-names></name><name><surname>Noble</surname><given-names>M</given-names></name><name><surname>DiCara</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Lichtenstein</surname><given-names>L</given-names></name><name><surname>Heiman</surname><given-names>DI</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>B</given-names></name><name><surname>Hodis</surname><given-names>E</given-names></name><name><surname>Baca</surname><given-names>S</given-names></name><name><surname>Dulak</surname><given-names>AM</given-names></name><name><surname>Lohr</surname><given-names>J</given-names></name><name><surname>Landau</surname><given-names>D-A</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Melendez-Zajgla</surname><given-names>J</given-names></name><name><surname>Hidalgo-Miranda</surname><given-names>A</given-names></name><name><surname>Koren</surname><given-names>A</given-names></name><name><surname>McCarroll</surname><given-names>SA</given-names></name><name><surname>Mora</surname><given-names>J</given-names></name><name><surname>Crompton</surname><given-names>B</given-names></name><name><surname>Onofrio</surname><given-names>R</given-names></name><name><surname>Parkin</surname><given-names>M</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Roberts</surname><given-names>CWM</given-names></name><name><surname>Biegel</surname><given-names>JA</given-names></name><name><surname>Stegmaier</surname><given-names>K</given-names></name><name><surname>Bass</surname><given-names>AJ</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Gordenin</surname><given-names>DA</given-names></name><name><surname>Sunyaev</surname><given-names>S</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title><source>Nature</source><volume>499</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="pmid">23770567</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Stojanov</surname><given-names>P</given-names></name><name><surname>Mermel</surname><given-names>CH</given-names></name><name><surname>Robinson</surname><given-names>JT</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Discovery and saturation analysis of cancer genes across 21 tumour types</article-title><source>Nature</source><volume>505</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/nature12912</pub-id><pub-id pub-id-type="pmid">24390350</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Lichtenstein</surname><given-names>L</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Lander</surname><given-names>E</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Comprehensive genomic characterization of head and neck squamous cell carcinomas</article-title><source>Nature</source><volume>517</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/nature14129</pub-id><pub-id pub-id-type="pmid">25631445</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiserson</surname><given-names>MDM</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>H-T</given-names></name><name><surname>Dobson</surname><given-names>JR</given-names></name><name><surname>Eldridge</surname><given-names>JV</given-names></name><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Papoutsaki</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>McLellan</surname><given-names>M</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Tamborero</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Ryslik</surname><given-names>GA</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes</article-title><source>Nature Genetics</source><volume>47</volume><fpage>106</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/ng.3168</pub-id><pub-id pub-id-type="pmid">25501392</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Birger</surname><given-names>C</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title><source>Cell Systems</source><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litan</surname><given-names>A</given-names></name><name><surname>Langhans</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer as a channelopathy: ion channels and pumps in tumor development and progression</article-title><source>Frontiers in Cellular Neuroscience</source><volume>9</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2015.00086</pub-id><pub-id pub-id-type="pmid">4362317</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Schilling</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Sucker</surname><given-names>A</given-names></name><name><surname>Livingstone</surname><given-names>E</given-names></name><name><surname>Jerby-Arnon</surname><given-names>L</given-names></name><name><surname>Zimmer</surname><given-names>L</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><name><surname>Satzger</surname><given-names>I</given-names></name><name><surname>Loquai</surname><given-names>C</given-names></name><name><surname>Grabbe</surname><given-names>S</given-names></name><name><surname>Vokes</surname><given-names>N</given-names></name><name><surname>Margolis</surname><given-names>CA</given-names></name><name><surname>Conway</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>MX</given-names></name><name><surname>Elmarakeby</surname><given-names>H</given-names></name><name><surname>Dietlein</surname><given-names>F</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Tracy</surname><given-names>A</given-names></name><name><surname>Gogas</surname><given-names>H</given-names></name><name><surname>Goldinger</surname><given-names>SM</given-names></name><name><surname>Utikal</surname><given-names>J</given-names></name><name><surname>Blank</surname><given-names>CU</given-names></name><name><surname>Rauschenberg</surname><given-names>R</given-names></name><name><surname>von Bubnoff</surname><given-names>D</given-names></name><name><surname>Krackhardt</surname><given-names>A</given-names></name><name><surname>Weide</surname><given-names>B</given-names></name><name><surname>Haferkamp</surname><given-names>S</given-names></name><name><surname>Kiecker</surname><given-names>F</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Garraway</surname><given-names>L</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Flaherty</surname><given-names>K</given-names></name><name><surname>Paschen</surname><given-names>A</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma</article-title><source>Nature Medicine</source><volume>25</volume><fpage>1916</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0654-5</pub-id><pub-id pub-id-type="pmid">31792460</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammoto</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>E</given-names></name><name><surname>Panigrahy</surname><given-names>D</given-names></name><name><surname>Kieran</surname><given-names>MW</given-names></name><name><surname>Mammoto</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression</article-title><source>The American Journal of Pathology</source><volume>183</volume><fpage>1293</fpage><lpage>1305</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.06.026</pub-id><pub-id pub-id-type="pmid">23928381</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martelotto</surname><given-names>LG</given-names></name><name><surname>Ng</surname><given-names>CK</given-names></name><name><surname>De Filippo</surname><given-names>MR</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Piscuoglio</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>RS</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Norton</surname><given-names>L</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Weigelt</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>84</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0484-1</pub-id><pub-id pub-id-type="pmid">4232638</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Raine</surname><given-names>KM</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Dawson</surname><given-names>KJ</given-names></name><name><surname>Haase</surname><given-names>K</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Universal Patterns of Selection in Cancer and Somatic Tissues</article-title><source>Cell</source><volume>171</volume><fpage>1029</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.042</pub-id><pub-id pub-id-type="pmid">29056346</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Jiménez</surname><given-names>F</given-names></name><name><surname>Muiños</surname><given-names>F</given-names></name><name><surname>Sentís</surname><given-names>I</given-names></name><name><surname>Deu-Pons</surname><given-names>J</given-names></name><name><surname>Reyes-Salazar</surname><given-names>I</given-names></name><name><surname>Arnedo-Pac</surname><given-names>C</given-names></name><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Pich</surname><given-names>O</given-names></name><name><surname>Bonet</surname><given-names>J</given-names></name><name><surname>Kranas</surname><given-names>H</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A compendium of mutational cancer driver genes</article-title><source>Nature Reviews Cancer</source><volume>20</volume><fpage>555</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/s41568-020-0290-x</pub-id><pub-id pub-id-type="pmid">32778778</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maslov</surname><given-names>S</given-names></name><name><surname>Sneppen</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Specificity and Stability in Topology of Protein Networks</article-title><source>Science</source><volume>296</volume><fpage>910</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1126/science.1065103</pub-id><pub-id pub-id-type="pmid">11988575</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mermel</surname><given-names>CH</given-names></name><name><surname>Schumacher</surname><given-names>SE</given-names></name><name><surname>Hill</surname><given-names>B</given-names></name><name><surname>Meyerson</surname><given-names>ML</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers</article-title><source>Genome Biology</source><volume>12</volume><elocation-id>R41</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2011-12-4-r41</pub-id><pub-id pub-id-type="pmid">21527027</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname><given-names>MA</given-names></name><name><surname>Cramer</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Molecular pathogenesis of endometrial and ovarian cancer</article-title><source>Cancer Biomarkers</source><volume>9</volume><fpage>287</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.3233/CBM-2011-0167</pub-id><pub-id pub-id-type="pmid">22112481</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moilanen</surname><given-names>JM</given-names></name><name><surname>Löffek</surname><given-names>S</given-names></name><name><surname>Kokkonen</surname><given-names>N</given-names></name><name><surname>Salo</surname><given-names>S</given-names></name><name><surname>Väyrynen</surname><given-names>JP</given-names></name><name><surname>Hurskainen</surname><given-names>T</given-names></name><name><surname>Manninen</surname><given-names>A</given-names></name><name><surname>Riihilä</surname><given-names>P</given-names></name><name><surname>Heljasvaara</surname><given-names>R</given-names></name><name><surname>Franzke</surname><given-names>C-W</given-names></name><name><surname>Kähäri</surname><given-names>V-M</given-names></name><name><surname>Salo</surname><given-names>T</given-names></name><name><surname>Mäkinen</surname><given-names>MJ</given-names></name><name><surname>Tasanen</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Significant Role of Collagen XVII And Integrin β4 in Migration and Invasion of The Less Aggressive Squamous Cell Carcinoma Cells</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>45057</elocation-id><pub-id pub-id-type="doi">10.1038/srep45057</pub-id><pub-id pub-id-type="pmid">28327550</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>BioCarta</article-title><source>Biotech Software &amp; Internet Report</source><volume>2</volume><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1089/152791601750294344</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Buchhalter</surname><given-names>I</given-names></name><name><surname>Morrissy</surname><given-names>AS</given-names></name><name><surname>Hovestadt</surname><given-names>V</given-names></name><name><surname>Weischenfeldt</surname><given-names>J</given-names></name><name><surname>Ehrenberger</surname><given-names>T</given-names></name><name><surname>Gröbner</surname><given-names>S</given-names></name><name><surname>Segura-Wang</surname><given-names>M</given-names></name><name><surname>Zichner</surname><given-names>T</given-names></name><name><surname>Rudneva</surname><given-names>VA</given-names></name><name><surname>Warnatz</surname><given-names>H-J</given-names></name><name><surname>Sidiropoulos</surname><given-names>N</given-names></name><name><surname>Phillips</surname><given-names>AH</given-names></name><name><surname>Schumacher</surname><given-names>S</given-names></name><name><surname>Kleinheinz</surname><given-names>K</given-names></name><name><surname>Waszak</surname><given-names>SM</given-names></name><name><surname>Erkek</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Worst</surname><given-names>BC</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Zapatka</surname><given-names>M</given-names></name><name><surname>Jäger</surname><given-names>N</given-names></name><name><surname>Chavez</surname><given-names>L</given-names></name><name><surname>Hutter</surname><given-names>B</given-names></name><name><surname>Bieg</surname><given-names>M</given-names></name><name><surname>Paramasivam</surname><given-names>N</given-names></name><name><surname>Heinold</surname><given-names>M</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Ishaque</surname><given-names>N</given-names></name><name><surname>Jäger-Schmidt</surname><given-names>C</given-names></name><name><surname>Imbusch</surname><given-names>CD</given-names></name><name><surname>Jugold</surname><given-names>A</given-names></name><name><surname>Hübschmann</surname><given-names>D</given-names></name><name><surname>Risch</surname><given-names>T</given-names></name><name><surname>Amstislavskiy</surname><given-names>V</given-names></name><name><surname>Gonzalez</surname><given-names>FGR</given-names></name><name><surname>Weber</surname><given-names>UD</given-names></name><name><surname>Wolf</surname><given-names>S</given-names></name><name><surname>Robinson</surname><given-names>GW</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cavalli</surname><given-names>FMG</given-names></name><name><surname>Luu</surname><given-names>B</given-names></name><name><surname>Ramaswamy</surname><given-names>V</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Koster</surname><given-names>J</given-names></name><name><surname>Ryzhova</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>Y-J</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Herold-Mende</surname><given-names>C</given-names></name><name><surname>Schuhmann</surname><given-names>M</given-names></name><name><surname>Ebinger</surname><given-names>M</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Mora</surname><given-names>J</given-names></name><name><surname>McLendon</surname><given-names>RE</given-names></name><name><surname>Jabado</surname><given-names>N</given-names></name><name><surname>Kumabe</surname><given-names>T</given-names></name><name><surname>Chuah</surname><given-names>E</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name><name><surname>Mungall</surname><given-names>AJ</given-names></name><name><surname>Mungall</surname><given-names>KL</given-names></name><name><surname>Thiessen</surname><given-names>N</given-names></name><name><surname>Tse</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>SJM</given-names></name><name><surname>Witt</surname><given-names>O</given-names></name><name><surname>Milde</surname><given-names>T</given-names></name><name><surname>Von Deimling</surname><given-names>A</given-names></name><name><surname>Capper</surname><given-names>D</given-names></name><name><surname>Korshunov</surname><given-names>A</given-names></name><name><surname>Yaspo</surname><given-names>M-L</given-names></name><name><surname>Kriwacki</surname><given-names>R</given-names></name><name><surname>Gajjar</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Fraenkel</surname><given-names>E</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Brors</surname><given-names>B</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Marra</surname><given-names>MA</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The whole-genome landscape of medulloblastoma subtypes</article-title><source>Nature</source><volume>547</volume><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/nature22973</pub-id><pub-id pub-id-type="pmid">28726821</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Guilt-by-association goes global</article-title><source>Nature</source><volume>403</volume><fpage>601</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1038/35001165</pub-id><pub-id pub-id-type="pmid">10688178</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozturk</surname><given-names>K</given-names></name><name><surname>Dow</surname><given-names>M</given-names></name><name><surname>Carlin</surname><given-names>DE</given-names></name><name><surname>Bejar</surname><given-names>R</given-names></name><name><surname>Carter</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine</article-title><source>Journal of Molecular Biology</source><volume>430</volume><fpage>2875</fpage><lpage>2899</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2018.06.016</pub-id><pub-id pub-id-type="pmid">29908887</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Page</surname><given-names>L</given-names></name><name><surname>Brin</surname><given-names>S</given-names></name><name><surname>Motwani</surname><given-names>R</given-names></name><name><surname>Winograd</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1999">1999</year><source>The PageRank Citation Ranking: Bringing Order to the Web</source><publisher-loc>California, United States</publisher-loc><publisher-name>Stanford InfoLab</publisher-name><ext-link ext-link-type="uri" xlink:href="http://ilpubs.stanford.edu:8090/422/">http://ilpubs.stanford.edu:8090/422/</ext-link></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>MR</given-names></name><name><surname>Huo</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Lesperance</surname><given-names>J</given-names></name><name><surname>Garancher</surname><given-names>A</given-names></name><name><surname>Wechsler-Reya</surname><given-names>RJ</given-names></name><name><surname>Zage</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Characterization of G-CSF receptor expression in medulloblastoma</article-title><source>Neuro-Oncology Advances</source><volume>2</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.1093/noajnl/vdaa062</pub-id><pub-id pub-id-type="pmid">32642714</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Petrov</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>NEArender-2.x</data-title><version designator="swh:1:rev:5829beb819c689790359f199547362a31d1a1d54">swh:1:rev:5829beb819c689790359f199547362a31d1a1d54</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/AveViort/NEArender-2.x">https://github.com/AveViort/NEArender-2.x</ext-link></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>NN</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>CF</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Lai</surname><given-names>MD</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Voltage-gated calcium channels: Novel targets for cancer therapy</article-title><source>Oncology Letters</source><volume>14</volume><fpage>2059</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.6457</pub-id><pub-id pub-id-type="pmid">28781648</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pico</surname><given-names>AR</given-names></name><name><surname>Kelder</surname><given-names>T</given-names></name><name><surname>van Iersel</surname><given-names>MP</given-names></name><name><surname>Hanspers</surname><given-names>K</given-names></name><name><surname>Conklin</surname><given-names>BR</given-names></name><name><surname>Evelo</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>WikiPathways: pathway editing for the people</article-title><source>PLOS Biology</source><volume>6</volume><elocation-id>e184</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0060184</pub-id><pub-id pub-id-type="pmid">18651794</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietsch</surname><given-names>T</given-names></name><name><surname>Mempel</surname><given-names>K</given-names></name><name><surname>Menzel</surname><given-names>Th</given-names></name><name><surname>Öckler</surname><given-names>R</given-names></name><name><surname>Welte</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Medulloblastoma Cells Constitutively Produce Granulocyte Colony-Stimulating Factor*</article-title><source>Klinische Pädiatrie</source><volume>202</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1055/s-2007-1025526</pub-id><pub-id pub-id-type="pmid">1697636</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugh</surname><given-names>TJ</given-names></name><name><surname>Weeraratne</surname><given-names>SD</given-names></name><name><surname>Archer</surname><given-names>TC</given-names></name><name><surname>Pomeranz Krummel</surname><given-names>DA</given-names></name><name><surname>Auclair</surname><given-names>D</given-names></name><name><surname>Bochicchio</surname><given-names>J</given-names></name><name><surname>Carneiro</surname><given-names>MO</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Erlich</surname><given-names>RL</given-names></name><name><surname>Greulich</surname><given-names>H</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Lennon</surname><given-names>NJ</given-names></name><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Meldrim</surname><given-names>J</given-names></name><name><surname>Ramos</surname><given-names>AH</given-names></name><name><surname>Ross</surname><given-names>MG</given-names></name><name><surname>Russ</surname><given-names>C</given-names></name><name><surname>Shefler</surname><given-names>E</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Sogoloff</surname><given-names>B</given-names></name><name><surname>Stojanov</surname><given-names>P</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Amani</surname><given-names>V</given-names></name><name><surname>Teider</surname><given-names>N</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Francois</surname><given-names>JP</given-names></name><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Crabtree</surname><given-names>GR</given-names></name><name><surname>Kautzman</surname><given-names>AG</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Jäger</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Cho</surname><given-names>Y-J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations</article-title><source>Nature</source><volume>488</volume><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nature11329</pub-id><pub-id pub-id-type="pmid">22820256</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remke</surname><given-names>M</given-names></name><name><surname>Ramaswamy</surname><given-names>V</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Medulloblastoma molecular dissection: the way toward targeted therapy</article-title><source>Current Opinion in Oncology</source><volume>25</volume><fpage>674</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1097/CCO.0000000000000008</pub-id><pub-id pub-id-type="pmid">24076581</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Predicting the functional impact of protein mutations: application to cancer genomics</article-title><source>Nucleic Acids Research</source><volume>39</volume><elocation-id>e118</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkr407</pub-id><pub-id pub-id-type="pmid">21727090</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyna</surname><given-names>MA</given-names></name><name><surname>Leiserson</surname><given-names>MDM</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hierarchical HotNet: identifying hierarchies of altered subnetworks</article-title><source>Bioinformatics</source><volume>34</volume><fpage>i972</fpage><lpage>i980</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty613</pub-id><pub-id pub-id-type="pmid">30423088</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyna</surname><given-names>MA</given-names></name><name><surname>Haan</surname><given-names>D</given-names></name><name><surname>Paczkowska</surname><given-names>M</given-names></name><name><surname>Verbeke</surname><given-names>LPC</given-names></name><name><surname>Vazquez</surname><given-names>M</given-names></name><name><surname>Kahraman</surname><given-names>A</given-names></name><name><surname>Pulido-Tamayo</surname><given-names>S</given-names></name><name><surname>Barenboim</surname><given-names>J</given-names></name><name><surname>Wadi</surname><given-names>L</given-names></name><name><surname>Dhingra</surname><given-names>P</given-names></name><name><surname>Shrestha</surname><given-names>R</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Pedersen</surname><given-names>JS</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Brunak</surname><given-names>S</given-names></name><name><surname>Izarzugaza</surname><given-names>JMG</given-names></name><name><surname>Khurana</surname><given-names>E</given-names></name><name><surname>Marchal</surname><given-names>K</given-names></name><name><surname>von Mering</surname><given-names>C</given-names></name><name><surname>Sahinalp</surname><given-names>SC</given-names></name><name><surname>Valencia</surname><given-names>A</given-names></name><collab>PCAWG Drivers and Functional Interpretation Working Group</collab><name><surname>Reimand</surname><given-names>J</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Pathway and network analysis of more than 2500 whole cancer genomes</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>729</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-14367-0</pub-id><pub-id pub-id-type="pmid">32024854</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risteli</surname><given-names>L</given-names></name><name><surname>Koivula</surname><given-names>MK</given-names></name><name><surname>Risteli</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Procollagen assays in cancer</article-title><source>Advances in Clinical Chemistry</source><volume>66</volume><fpage>79</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/b978-0-12-801401-1.00003-7</pub-id><pub-id pub-id-type="pmid">25344986</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>G</given-names></name><name><surname>Parker</surname><given-names>M</given-names></name><name><surname>Kranenburg</surname><given-names>TA</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Phoenix</surname><given-names>TN</given-names></name><name><surname>Hedlund</surname><given-names>E</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Chalhoub</surname><given-names>N</given-names></name><name><surname>Baker</surname><given-names>SJ</given-names></name><name><surname>Huether</surname><given-names>R</given-names></name><name><surname>Kriwacki</surname><given-names>R</given-names></name><name><surname>Curley</surname><given-names>N</given-names></name><name><surname>Thiruvenkatam</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Rusch</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Becksfort</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Easton</surname><given-names>J</given-names></name><name><surname>Vadodaria</surname><given-names>B</given-names></name><name><surname>Onar-Thomas</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><name><surname>Paugh</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Kawauchi</surname><given-names>D</given-names></name><name><surname>Roussel</surname><given-names>MF</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Ellison</surname><given-names>DW</given-names></name><name><surname>Lau</surname><given-names>CC</given-names></name><name><surname>Bouffet</surname><given-names>E</given-names></name><name><surname>Hassall</surname><given-names>T</given-names></name><name><surname>Gururangan</surname><given-names>S</given-names></name><name><surname>Cohn</surname><given-names>R</given-names></name><name><surname>Fulton</surname><given-names>RS</given-names></name><name><surname>Fulton</surname><given-names>LL</given-names></name><name><surname>Dooling</surname><given-names>DJ</given-names></name><name><surname>Ochoa</surname><given-names>K</given-names></name><name><surname>Gajjar</surname><given-names>A</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Gilbertson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Novel mutations target distinct subgroups of medulloblastoma</article-title><source>Nature</source><volume>488</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/nature11213</pub-id><pub-id pub-id-type="pmid">22722829</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodchenkov</surname><given-names>I</given-names></name><name><surname>Babur</surname><given-names>O</given-names></name><name><surname>Luna</surname><given-names>A</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Wong</surname><given-names>JV</given-names></name><name><surname>Fong</surname><given-names>D</given-names></name><name><surname>Franz</surname><given-names>M</given-names></name><name><surname>Siper</surname><given-names>MC</given-names></name><name><surname>Cheung</surname><given-names>M</given-names></name><name><surname>Wrana</surname><given-names>M</given-names></name><name><surname>Mistry</surname><given-names>H</given-names></name><name><surname>Mosier</surname><given-names>L</given-names></name><name><surname>Dlin</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Q</given-names></name><name><surname>O’Callaghan</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Elder</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>PT</given-names></name><name><surname>Dallago</surname><given-names>C</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Demir</surname><given-names>E</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pathway Commons 2019 Update: integration, analysis and exploration of pathway data</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D489</fpage><lpage>D497</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz946</pub-id><pub-id pub-id-type="pmid">31647099</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Fasan</surname><given-names>O</given-names></name><name><surname>Block</surname><given-names>J</given-names></name><name><surname>Pal</surname><given-names>S</given-names></name><name><surname>Elvin</surname><given-names>JA</given-names></name><name><surname>Schrock</surname><given-names>AB</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Nozad</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Jeong Lee</surname><given-names>H</given-names></name><name><surname>Sheehan</surname><given-names>CE</given-names></name><name><surname>Jones</surname><given-names>DM</given-names></name><name><surname>Vergilio</surname><given-names>J-A</given-names></name><name><surname>Ramkissoon</surname><given-names>S</given-names></name><name><surname>Severson</surname><given-names>E</given-names></name><name><surname>Daniel</surname><given-names>S</given-names></name><name><surname>Fabrizio</surname><given-names>D</given-names></name><name><surname>Frampton</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>Gay</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>ALK</italic> Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy</article-title><source>The Oncologist</source><volume>22</volume><fpage>1444</fpage><lpage>1450</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2016-0488</pub-id><pub-id pub-id-type="pmid">29079636</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rousselle</surname><given-names>P</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Laminin 332 in cancer: When the extracellular matrix turns signals from cell anchorage to cell movement</article-title><source>Seminars in Cancer Biology</source><volume>62</volume><fpage>149</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.09.026</pub-id><pub-id pub-id-type="pmid">31639412</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>T</given-names></name><name><surname>Ogris</surname><given-names>C</given-names></name><name><surname>Sonnhammer</surname><given-names>ELL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FunCoup 3.0: database of genome-wide functional coupling networks</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D380</fpage><lpage>D388</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt984</pub-id><pub-id pub-id-type="pmid">24185702</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>Y</given-names></name><name><surname>Miladi</surname><given-names>M</given-names></name><name><surname>Dukare</surname><given-names>S</given-names></name><name><surname>Boulay</surname><given-names>K</given-names></name><name><surname>Caudron-Herger</surname><given-names>M</given-names></name><name><surname>Groß</surname><given-names>M</given-names></name><name><surname>Backofen</surname><given-names>R</given-names></name><name><surname>Diederichs</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A pan-cancer analysis of synonymous mutations</article-title><source>Nature Communications</source><volume>10</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41467-019-10489-2</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>NL</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>G</given-names></name><name><surname>Ng</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>SIFT web server: predicting effects of amino acid substitutions on proteins</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>W452</fpage><lpage>W457</lpage><pub-id pub-id-type="doi">10.1093/nar/gks539</pub-id><pub-id pub-id-type="pmid">22689647</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stelzer</surname><given-names>G</given-names></name><name><surname>Dalah</surname><given-names>I</given-names></name><name><surname>Stein</surname><given-names>T</given-names></name><name><surname>Satanower</surname><given-names>Y</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Nativ</surname><given-names>N</given-names></name><name><surname>Oz-Levi</surname><given-names>D</given-names></name><name><surname>Olender</surname><given-names>T</given-names></name><name><surname>Belinky</surname><given-names>F</given-names></name><name><surname>Bahir</surname><given-names>I</given-names></name><name><surname>Krug</surname><given-names>H</given-names></name><name><surname>Perco</surname><given-names>P</given-names></name><name><surname>Mayer</surname><given-names>B</given-names></name><name><surname>Kolker</surname><given-names>E</given-names></name><name><surname>Safran</surname><given-names>M</given-names></name><name><surname>Lancet</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>In-silico human genomics with GeneCards</article-title><source>Human Genomics</source><volume>5</volume><elocation-id>709</elocation-id><pub-id pub-id-type="doi">10.1186/1479-7364-5-6-709</pub-id><pub-id pub-id-type="pmid">22155609</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stracquadanio</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wallace</surname><given-names>MD</given-names></name><name><surname>Grawenda</surname><given-names>AM</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Hewitt</surname><given-names>J</given-names></name><name><surname>Zeron-Medina</surname><given-names>J</given-names></name><name><surname>Castro-Giner</surname><given-names>F</given-names></name><name><surname>Tomlinson</surname><given-names>IP</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name><name><surname>Cygan</surname><given-names>KJ</given-names></name><name><surname>Fairbrother</surname><given-names>WG</given-names></name><name><surname>Thomas</surname><given-names>LF</given-names></name><name><surname>Sætrom</surname><given-names>P</given-names></name><name><surname>Gemignani</surname><given-names>F</given-names></name><name><surname>Landi</surname><given-names>S</given-names></name><name><surname>Schuster-Böckler</surname><given-names>B</given-names></name><name><surname>Bell</surname><given-names>DA</given-names></name><name><surname>Bond</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The importance of p53 pathway genetics in inherited and somatic cancer genomes</article-title><source>Nature Reviews. Cancer</source><volume>16</volume><fpage>251</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.15</pub-id><pub-id pub-id-type="pmid">27009395</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweet-Cordero</surname><given-names>EA</given-names></name><name><surname>Biegel</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The genomic landscape of pediatric cancers: Implications for diagnosis and treatment</article-title><source>Science (New York, N.Y.)</source><volume>363</volume><fpage>1170</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1126/science.aaw3535</pub-id><pub-id pub-id-type="pmid">30872516</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tajada</surname><given-names>S</given-names></name><name><surname>Villalobos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Calcium Permeable Channels in Cancer Hallmarks</article-title><source>Frontiers in Pharmacology</source><volume>11</volume><elocation-id>968</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2020.00968</pub-id><pub-id pub-id-type="pmid">32733237</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamborero</surname><given-names>D</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Perez-Llamas</surname><given-names>C</given-names></name><name><surname>Deu-Pons</surname><given-names>J</given-names></name><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>Reimand</surname><given-names>J</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Comprehensive identification of mutational cancer driver genes across 12 tumor types</article-title><source>Scientific Reports</source><volume>3</volume><elocation-id>2650</elocation-id><pub-id pub-id-type="doi">10.1038/srep02650</pub-id><pub-id pub-id-type="pmid">24084849</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Cancer Genome Atlas Research Network</collab><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Shaw</surname><given-names>KRM</given-names></name><name><surname>Ozenberger</surname><given-names>BA</given-names></name><name><surname>Ellrott</surname><given-names>K</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1113</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1038/ng.2764</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torkamani</surname><given-names>A</given-names></name><name><surname>Schork</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of rare cancer driver mutations by network reconstruction</article-title><source>Genome Research</source><volume>19</volume><fpage>1570</fpage><lpage>1578</lpage><pub-id pub-id-type="doi">10.1101/gr.092833.109</pub-id><pub-id pub-id-type="pmid">19574499</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torkamani</surname><given-names>A</given-names></name><name><surname>Verkhivker</surname><given-names>G</given-names></name><name><surname>Schork</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cancer driver mutations in protein kinase genes</article-title><source>Cancer Letters</source><volume>281</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.11.008</pub-id><pub-id pub-id-type="pmid">19081671</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tranchevent</surname><given-names>LC</given-names></name><name><surname>Capdevila</surname><given-names>FB</given-names></name><name><surname>Nitsch</surname><given-names>D</given-names></name><name><surname>De Moor</surname><given-names>B</given-names></name><name><surname>De Causmaecker</surname><given-names>P</given-names></name><name><surname>Moreau</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A guide to web tools to prioritize candidate genes</article-title><source>Briefings in Bioinformatics</source><volume>12</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1093/bib/bbq007</pub-id><pub-id pub-id-type="pmid">21278374</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuruta</surname><given-names>D</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Imanishi</surname><given-names>H</given-names></name><name><surname>Sugawara</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>JCR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Laminin-332-integrin interaction: A target for cancer therapy?</article-title><source>Current Medicinal Chemistry</source><volume>15</volume><fpage>1968</fpage><lpage>1975</lpage><pub-id pub-id-type="doi">10.2174/092986708785132834</pub-id><pub-id pub-id-type="pmid">18691052</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>JF</given-names></name><name><surname>Van Hecke</surname><given-names>W</given-names></name><name><surname>Adriaansen</surname><given-names>EJM</given-names></name><name><surname>Jansen</surname><given-names>MK</given-names></name><name><surname>Bouma</surname><given-names>RG</given-names></name><name><surname>Villacorta Hidalgo</surname><given-names>J</given-names></name><name><surname>Fisch</surname><given-names>P</given-names></name><name><surname>Broekhuizen</surname><given-names>R</given-names></name><name><surname>Spliet</surname><given-names>WGM</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Bovenschen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma</article-title><source>OncoImmunology</source><volume>7</volume><elocation-id>e1398877</elocation-id><pub-id pub-id-type="doi">10.1080/2162402X.2017.1398877</pub-id><pub-id pub-id-type="pmid">29399402</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Velculescu</surname><given-names>VE</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cancer genome landscapes</article-title><source>Science (New York, N.Y.)</source><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmid">23539594</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>From human genome to cancer genome: the first decade</article-title><source>Genome Research</source><volume>23</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1101/gr.157602.113</pub-id><pub-id pub-id-type="pmid">23817046</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>C</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name><name><surname>Kersting</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>J</given-names></name><name><surname>Aust</surname><given-names>D</given-names></name><name><surname>Knösel</surname><given-names>T</given-names></name><name><surname>Rümmele</surname><given-names>P</given-names></name><name><surname>Jahnke</surname><given-names>B</given-names></name><name><surname>Hentrich</surname><given-names>V</given-names></name><name><surname>Rückert</surname><given-names>F</given-names></name><name><surname>Niedergethmann</surname><given-names>M</given-names></name><name><surname>Weichert</surname><given-names>W</given-names></name><name><surname>Bahra</surname><given-names>M</given-names></name><name><surname>Schlitt</surname><given-names>HJ</given-names></name><name><surname>Settmacher</surname><given-names>U</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Büchler</surname><given-names>M</given-names></name><name><surname>Saeger</surname><given-names>H-D</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name><name><surname>Pilarsky</surname><given-names>C</given-names></name><name><surname>Grützmann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes</article-title><source>PLOS Computational Biology</source><volume>8</volume><elocation-id>e1002511</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002511</pub-id><pub-id pub-id-type="pmid">22615549</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74010.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Robles-Espinoza</surname><given-names>C Daniela</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>International Laboratory for Human Genome Research</institution><country>Mexico</country></aff></contrib></contrib-group><related-object id="sa0ro1" link-type="continued-by" object-id="10.1101/2021.10.04.463007" object-id-type="id" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.04.463007"/></front-stub><body><p>In this work, Petrov and Alexeyenko present a novel network-based method to infer cancer driver genes that is not based on frequency of mutations, NEAdriver, and evaluate its performance across a large dataset. This manuscript addresses a topic of high interest in the cancer genomics community and is a welcome addition to the literature.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74010.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Robles-Espinoza</surname><given-names>C Daniela</given-names></name><role>Reviewing Editor</role><aff><institution>International Laboratory for Human Genome Research</institution><country>Mexico</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Gonzalez-Perez</surname><given-names>Abel</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.10.04.463007">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.10.04.463007v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Individualized discovery of rare cancer drivers in global network context&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Aleksandra Walczak as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Abel Gonzalez-Perez (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. The three reviewers agreed that the authors should provide a reasonable calculation of the rate of false positives that their method produces, as at the moment is hard to evaluate what this number may be. The authors do not seem to correct for the background mutation rate of genes in the calculation of MutSet. This may result in identifying false positive driver genes with abnormally high number of mutations across cohorts due to known covariates of the mutation rate, such as the replication time or the level of transcription. Correctly estimating the background mutation rate of genes across tumors is a key tenet of methods that search for signals of positive selection in genes. For further explanation on this subject see PMID 23770567 and PMID 29056346. This may explain why known highly mutated non driver genes like TTN, RYR1 and others appear as significant recurrently across different cohorts. This issue is key for any method that uses mutation data to identify driver genes and must be addressed by the authors. A reviewer also adds adds that one way to calculate the rate of false positives would be to compile a list of known artifactual genes identified by methods aiming at detecting signals of positive selection in their mutational pattern across tumors. Computing the overlap of the output of their method with this list across cohorts could provide such estimate. An example of such a list is also provided in the supplementary material of this paper: PMID 32778778.</p><p>2. Reviewers also noted that the paper would benefit from a clearer presentation of the algorithm. Specifically:</p><p>a) Have the authors performed any technical filtering of the mutations? If not, how can they ensure that their results are not affected by potential sequencing artifacts or germline contamination?</p><p>b) The authors state that &quot;The procedure evaluated likelihood of each genomic alteration (either PM or CNA) being a driver in each tumor genome.&quot; However, apparently results are only provided at the level of gene-cohort. Can this be addressed, please?</p><p>c) How are different sample-specific MutSet values converted into a single cohort-wise value per gene?</p><p>d) Is the only difference between the MutSet channel and the summary computed in PathReg channel the fact that in the former the NEA is computed only for mutated genes, while in the latter it is computed for all genes in the network?</p><p>e) When explaining the PathReg, the authors state that &quot;the μic value would reflect a general propensity of i to interact with constellations of putative cancer genes&quot; and that &quot;The μic profiles were rather scarce due to rare occurrence in MGS of true drivers that would interact with a given gene i&quot;. However, in the μic measures the NEA score of each gene with the mutated genes across samples, not with previously identified driver genes. Can the authors clarify this please?</p><p>f) How are p-values for the MutSet algorithm computed?</p><p>g) How were the cutoff qvalues of 0.05 and 0.01 selected? How do they compare in terms of number of genes that pass each?</p><p>h) Could the authors clarify the rationale under the selection of nine TCGA cohorts (among 34) to apply their algorithm?</p><p>i) It is not clear to some reviewers why the authors described their algorithm as &quot;individualized&quot;. It may give the impression that it is aimed at identifying alterations driving a patient's tumor, rather than genes that are cancer drivers across tumors. Could this terminology be clarified please?</p><p>3. Please articulate more clearly what the conclusions of the study are. Results should provide a big picture summary of the method that is understandable to non-experts, while technical details might be better presented in the methods. Specifically, it would be good to answer the following questions:</p><p>a) How many driver genes are identified in each cohort? This information does not seem easy to find. A long supplementary Table contains q-values for all genes (&gt;19,000) across all cohorts, but this is impractical to navigate. It would be easier to have a table containing only significant genes, with the numbers reported in the text and presented in Figures.</p><p>b) It was brought up that KEGG Pathways in Cancer may not be a good standard to evaluate the performance of an algorithm aimed at identifying driver genes from their mutations across tumors. Reasons are: First, they contain manually selected genes that fit functional interaction in pathways, which may leave out some relevant genes. Second, because they contain genes connected through functional interactions into pathways, some of them may not be drivers at all, but only connected to drivers. Since the NEAdriver method exploits network connections to identify significant genes it may not be surprising that its output shows the best overlap with these curated pathways. It may be better to do a more comprehensive comparison with gold standard lists of cancer driver genes, such as the Cancer Gene Census (this would be solved by doing the false positive rate calculation described in point 1).</p><p>c) What is the gold standard set used to compute the ROC curves shown in Figure 2? From the text it would seem that genes in KEGG pathways are used as true positives, but these are also evaluated, so the evaluation dataset must be external. Can the authors please clarify this?</p><p>d) There's a plethora of published methods that identify signals of positive selection in the mutational pattern of genes across tumors. For articles that summarize groups of such methods, see PMID 29625053 or PMID 32778778. This paper should include a thorough benchmark and comparison of the NEAdriver method to these state of the art algorithms.</p><p>e) Please specify which version of the genomics data was was used (the gcs.cancer.gov portal hosts multiple versions from the TCGA data -Hg19 and Hg38, multiple file formats). Linked to this – why did the authors not use a more recently processed version of the TCGA data than the one on GDC portal (e.g. there are multiple pan-cancer follow up publications)? And, could it be specified what type of data was downloaded from TCGA (VCFs, MAFs, Or BAMs)? This is not specified in the methods and without this information it is hard to assess what the authors have done to ensure that their variant calling is accurate. For example, a reviewer mentioned that there are a number of similar genes in the heatmaps (ITGB6, ITGA8, ITGAL etc). These may act in the same pathways but are also paralogues – how can the authors be sure that mutations detected in these are real and not an issue of mismapping?</p><p>f) Finally, more generally, is there a new class of driver genes that can be identified based on the authors' approach that could not be understood based on previous studies, or alternatively, could this method/strategies be expanded to predict other phenotypes than driver genes? Was a new cancer gene or driver mutation discovered that could not be explained previously and that can now be viewed in a new perspective based on the authors' work? Highlighting a few of these examples would make the impact of their paper much stronger.</p><p>4. Please add a code availability section (e.g. GitHub repository).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74010.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The three reviewers agreed that the authors should provide a reasonable calculation of the rate of false positives that their method produces, as at the moment is hard to evaluate what this number may be. The authors do not seem to correct for the background mutation rate of genes in the calculation of MutSet. This may result in identifying false positive driver genes with abnormally high number of mutations across cohorts due to known covariates of the mutation rate, such as the replication time or the level of transcription. Correctly estimating the background mutation rate of genes across tumors is a key tenet of methods that search for signals of positive selection in genes. For further explanation on this subject see PMID 23770567 and PMID 29056346. This may explain why known highly mutated non driver genes like TTN, RYR1 and others appear as significant recurrently across different cohorts. This issue is key for any method that uses mutation data to identify driver genes and must be addressed by the authors. A reviewer also adds adds that one way to calculate the rate of false positives would be to compile a list of known artifactual genes identified by methods aiming at detecting signals of positive selection in their mutational pattern across tumors. Computing the overlap of the output of their method with this list across cohorts could provide such estimate. An example of such a list is also provided in the supplementary material of this paper: PMID 32778778.</p></disp-quote><p>At the initial stage of this project, we spent much time investigating associations between frequency and other input or background characteristics and the NEAdriver. Somewhat surprisingly but consistently with nature of the algorithm, we did not find any strong relations. Unfortunately, we took this as self-evident and never reported it in the manuscript. Now we did our best to prove that it indeed did not significantly affect the reported results. In section “Rates of driver discovery rate versus mutation frequency and possible confounders” we now presented an in-depth analysis of NEAdriver results in relation to the factors pointed by reviewers.</p><p>From the papers which you recommended, we obtained lists of known or suggested artefactual genes: Martincorena et al., (2017), Lawrence et al., (2014), and Martínez-Jiménez (2020), as well as the whole category of olfactory receptors mentioned as implausible drivers by e.g. Lawrence et al., (2014). These genes were color- and text-marked in the new analysis and included as a co-factor in the linear model analyses (see also below). Further, similarly to Figure 3 by Lawrence et al., (2013) we evaluated influence of known confounders (gene length, replication rate, expression level, and total mutation burden per sample) on the NEAdriver predictions in 4-way linear models. While Lawrence and co-authors demonstrated strong correlations of mutation rate versus replication or expression, respective correlations of NEAdriver score were not strong at all. NEAdriver predictions stronger associated with CDS length – but the same tendency was noted in all the analyzed gene sets (see new Figure Supplement to Figure 4). Also, genes of all the computational sets more frequently contained point mutations and had higher mutation frequency per b.p. length, both absolute and normalized by genome-specific mutation load. The same was also true for the driver set by Lawrence et al., (2014), which supposedly would be least affected by these factors. Otherwise, probability of being predicted by NEAdriver after adjustment for gene length and TMB proved to be weak.</p><p>New Suppl. File 5 displays artifactual genes which surpassed significance threshold q&lt;0.05, so that we see 1…13 genes per cohort. Interestingly, our previous estimates of false discovery rates with 2 alternative methods ranged between 20 and 80% – while only 0.5…3% of the NEAdriver predictions were found in the artifact gene lists (upper right legends in Suppl. File 5). For comparison, the same genes made up 1…9% of the alternative computational sets.</p><p>Lawrence et al., (2013) pointed that several “false positives” had cropped up and rooted in cancer genome studies. In Discussion, we considered in detail one such gene, titin and provided alternative explanations of how, despite the apparently high length, it might still be involved in carcinogenesis. Therefore, we decided to not exclude any artifactual genes suggested in the mentioned publications but instead labeled them in last columns of the new final result tables (Supplementary File 8). Also, Figure 2B is now made upon exclusion of such genes from all the sets (which did not lead to any significant changes in the tree topology).</p><disp-quote content-type="editor-comment"><p>2. Reviewers also noted that the paper would benefit from a clearer presentation of the algorithm. Specifically:</p><p>a) Have the authors performed any technical filtering of the mutations? If not, how can they ensure that their results are not affected by potential sequencing artifacts or germline contamination?</p></disp-quote><p>Thank you for this question. The mutation sets per sample were used from MAF files as delivered by TCGA (level 3 data) and from MAF files or curated lists for MB related projects. This setting corresponds to the suggested role of NEAdriver algorithm, which is evaluation of any reported mutations and filtering out passenger ones based on network connectivity, similarly to real-life clinical evaluation of in a molecular tumor board.</p><disp-quote content-type="editor-comment"><p>b) The authors state that &quot;The procedure evaluated likelihood of each genomic alteration (either PM or CNA) being a driver in each tumor genome.&quot; However, apparently results are only provided at the level of gene-cohort. Can this be addressed, please?</p></disp-quote><p>Indeed, for the sake of reducing file size we decided to submit the resulting table in a “compact” format, i.e. per gene&amp;cohort rather than per sample&amp;gene&amp;cohort. Now (see also the next question) we have instead generated and submitted separate, per cohort Excel files which contain ~1 million rows in total (Suppl. File 8).</p><disp-quote content-type="editor-comment"><p>c) How are different sample-specific MutSet values converted into a single cohort-wise value per gene?</p></disp-quote><p>Thank you for this question. For the initial submission we summarized the MutSet values with Fisher’s formula for combining p-values, which was described only as a comment in the Excel table header – likely not noticeable. Now we realized that this way of presentation was extremely unfortunate. Beyond raising the current question, the Fisher’s approach was misleading and resulted in an incorrect presentation of final NEAdriver predictions, since these values were then multiplied with PathReg p. We also noticed that it emphasized the artefactual genes much stronger than they deserved by their NEAdriver scores. This calculation was only applied in this table and is now fully abandoned. Instead, we presented the genuine NEAdriver results in full tables (see answer to the previous question).</p><disp-quote content-type="editor-comment"><p>d) Is the only difference between the MutSet channel and the summary computed in PathReg channel the fact that in the former the NEA is computed only for mutated genes, while in the latter it is computed for all genes in the network?</p></disp-quote><p>No, the major difference is that the MutSet scores are limited to own sample’s mutations, whereas the PathReg score for the same gene would be based on a sum of such scores against ALL samples, including those where it was wild type. So PathReg is computed “across samples, via external genes and pathways” rather than “within a specific mutated gene set”. As a result, MutSet and PathReg are quite uncorrelated (see also the next reply). We emphasized this difference in the revised version.</p><disp-quote content-type="editor-comment"><p>e) When explaining the PathReg, the authors state that &quot;the μic value would reflect a general propensity of i to interact with constellations of putative cancer genes&quot; and that &quot;The μic profiles were rather scarce due to rare occurrence in MGS of true drivers that would interact with a given gene i&quot;. However, in the μic measures the NEA score of each gene with the mutated genes across samples, not with previously identified driver genes. Can the authors clarify this please?</p></disp-quote><p>Thank you for pointing to this part which indeed required clarification. The idea was that PathReg gathers scarce information from <italic>implicit</italic> drivers (which would be very few per sample) without input from previous knowledge. All mutations have <italic>a priori</italic> equal weights, but the signal from passengers should be negligible and is filtered out. We suppose that this “explicit vs. implicit” difference was unexplained and caused the misunderstanding. We elaborated on this in the text. We should also mention that we tested an extra channel for NEAdriver against most frequent mutated genes (similarly to NetSig algorithm) but it did not produce any extra benefit for NEAdriver performance and was not used.</p><disp-quote content-type="editor-comment"><p>f) How are p-values for the MutSet algorithm computed?</p></disp-quote><p>Thank you for noticing this, we missed to explain it. Briefly, the normally distributed (under null) NEA z-scores were converted to p-values with a standard R function (pnorm). We added this to Methods now.</p><disp-quote content-type="editor-comment"><p>g) How were the cutoff qvalues of 0.05 and 0.01 selected? How do they compare in terms of number of genes that pass each?</p></disp-quote><p>The cutoff levels affected discovery rates rather weakly. In particular, the agreement with gold standard sets was satisfactory already at q&lt;0.2 and did not drop steeply after that (Figure 3C,D,E,F). Thus the two q-value cutoffs were chosen quite arbitrarily, just to provide a certain alternative. The new Table 1 allows comparing the cutoff effects on the number of genes. Under q&lt;0.05 the fractions of drivers were 14…67% larger than under q&lt;0.01. We also mentioned it in the text (page 5).</p><disp-quote content-type="editor-comment"><p>h) Could the authors clarify the rationale under the selection of nine TCGA cohorts (among 34) to apply their algorithm?</p></disp-quote><p>This work was not a part of TCGA or a PanCancer project. Our major purpose of having multiple cohorts was to investigate the method’s efficiency over a range of typical mutation frequencies per sample. By the moment of project start, we selected TCGA cohorts with highest number of samples with exome-seq and other potentially relevant data. Medulloblastoma was introduced for having least somatic mutations per sample.</p><disp-quote content-type="editor-comment"><p>i) It is not clear to some reviewers why the authors described their algorithm as &quot;individualized&quot;. It may give the impression that it is aimed at identifying alterations driving a patient's tumor, rather than genes that are cancer drivers across tumors. Could this terminology be clarified please?</p></disp-quote><p>By using this word we referred to the classification of driver discovery methods into those collecting cohort-wise statistics and those looking at individual patient/sample features, NEAdriver belongs to the latter category. So, the impression was actually correct, but it is just “individualized” rather than fully “individual” because PathReg, while also using individual samples, still produces cohort-wise scores. We now elaborated on this in Abstract.</p><disp-quote content-type="editor-comment"><p>3. Please articulate more clearly what the conclusions of the study are. Results should provide a big picture summary of the method that is understandable to non-experts, while technical details might be better presented in the methods. Specifically, it would be good to answer the following questions:</p><p>a) How many driver genes are identified in each cohort? This information does not seem easy to find. A long supplementary Table contains q-values for all genes (&gt;19,000) across all cohorts, but this is impractical to navigate. It would be easier to have a table containing only significant genes, with the numbers reported in the text and presented in Figures.</p></disp-quote><p>Thank you for this suggestion. We have created a new Table 1 with counts and percentages of unique genes and mutations per cohort predicted with the channels and altogether.</p><disp-quote content-type="editor-comment"><p>b) It was brought up that KEGG Pathways in Cancer may not be a good standard to evaluate the performance of an algorithm aimed at identifying driver genes from their mutations across tumors. Reasons are: First, they contain manually selected genes that fit functional interaction in pathways, which may leave out some relevant genes. Second, because they contain genes connected through functional interactions into pathways, some of them may not be drivers at all, but only connected to drivers. Since the NEAdriver method exploits network connections to identify significant genes it may not be surprising that its output shows the best overlap with these curated pathways. It may be better to do a more comprehensive comparison with gold standard lists of cancer driver genes, such as the Cancer Gene Census (this would be solved by doing the false positive rate calculation described in point 1).</p></disp-quote><p>Thank you for these suggestions. The KEGG pathways were used as a reference which is both human-curated and cancer site-specific (and we did believe that having genes “manually selected” and “only connected to drivers” would be an advantage). But now we have complemented the references with the suggested site-specific Cancer Gene Census, Martincorena et al., (2017) as well as IntOGen genes sets. In some cohorts, using CGC as a standard produced even more optimistic results than KEGG.</p><disp-quote content-type="editor-comment"><p>c) What is the gold standard set used to compute the ROC curves shown in Figure 2? From the text it would seem that genes in KEGG pathways are used as true positives, but these are also evaluated, so the evaluation dataset must be external. Can the authors please clarify this?</p></disp-quote><p>We assume Figure 3 was meant here (Figure 2 is a heatmap). In addition to the single reference set in Figure 3E,F we now employed benchmarks based on Cancer Gene Census, IntOGen, and the list of “369 known cancer genes” (Martincorena et al., 2017). These now appear as novel lines in Figures 3E and F (the dataset descriptions can be found in Methods). Also, the legend was probably misleading. Under “KEGG” here we meant site-specific cancer pathways for the cohorts rather than ALL pathways. When not available from KEGG (as for MB cohort), custom literature-based sets were used. Since there was no way to find an absolutely external, non-overlapping set for this analysis, in Figure 3A,B,C,D we used as many as 12 different gene sets.</p><disp-quote content-type="editor-comment"><p>d) There's a plethora of published methods that identify signals of positive selection in the mutational pattern of genes across tumors. For articles that summarize groups of such methods, see PMID 29625053 or PMID 32778778. This paper should include a thorough benchmark and comparison of the NEAdriver method to these state of the art algorithms.</p></disp-quote><p>We have now included both 29625053 (Bailey et al., 2020) and 32778778 (IntOGen) in the analysis. We also note that many of the methods which MC3 project combined (Bailey et al., 2018) had been analyzed individually in our manuscript.</p><disp-quote content-type="editor-comment"><p>e) Please specify which version of the genomics data was was used (the gcs.cancer.gov portal hosts multiple versions from the TCGA data -Hg19 and Hg38, multiple file formats). Linked to this – why did the authors not use a more recently processed version of the TCGA data than the one on GDC portal (e.g. there are multiple pan-cancer follow up publications)? And, could it be specified what type of data was downloaded from TCGA (VCFs, MAFs, Or BAMs)? This is not specified in the methods and without this information it is hard to assess what the authors have done to ensure that their variant calling is accurate. For example, a reviewer mentioned that there are a number of similar genes in the heatmaps (ITGB6, ITGA8, ITGAL etc). These may act in the same pathways but are also paralogues – how can the authors be sure that mutations detected in these are real and not an issue of mismapping?</p></disp-quote><p>Thank you for this remark. We used MAF files based on Hg19. Regarding the TCGA data, we considered GDC being the most official source, enabling most uniform data processing and used as such by many (all?) PanCancer projects. Although for clinical data, which significantly changed over the years, we did use a PanCancer update by Liu et al., (2019). These details are now provided in the manuscript.</p><disp-quote content-type="editor-comment"><p>f) Finally, more generally, is there a new class of driver genes that can be identified based on the authors' approach that could not be understood based on previous studies, or alternatively, could this method/strategies be expanded to predict other phenotypes than driver genes? Was a new cancer gene or driver mutation discovered that could not be explained previously and that can now be viewed in a new perspective based on the authors' work? Highlighting a few of these examples would make the impact of their paper much stronger.</p></disp-quote><p>Thank you for this suggestion. We now introduced (see last section of Results) a presentation of quite extensive groups of genes that were frequently predicted (in about half of the studied cohorts): integrins, laminins, and collagens. Despite being mutated in nearly each genomic sample, such genes were so far mostly overlooked, probably because of their “non-signaling” roles. We took extreme care of making sure that these are not artifacts and indeed can provide a novel view angle at carcinogenesis.</p><disp-quote content-type="editor-comment"><p>4. Please add a code availability section (e.g. GitHub repository).</p></disp-quote><p>Thank you for bringing this into our attention, code availability section was added.</p></body></sub-article></article>